Rapidly maturing fluroscent proteins and methods for using the same

ABSTRACT

Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type  Discosoma  sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application serial no.PCT/US02/40539 filed on Dec. 18, 2002; which application, pursuant to 35U.S.C. §119 (e), claims priority to the filing date of U.S. ProvisionalPatent Application Ser. No. 60/341,723 filed Dec. 19, 2001; thedisclosures of which are herein incorporated by reference.

ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

The Government may own rights in the present invention pursuant to GrantNumber 9875939 from the National Science Foundation.

INTRODUCTION

1. Field of the Invention

The field of this invention is fluorescent proteins.

2. Background of the Invention

Labeling is a tool for marking a protein, cell, or organism of interestand plays a prominent role in many biochemistry, molecular biology andmedical diagnostic applications. A variety of different labels have beendeveloped, including radiolabels, chromolabels, fluorescent labels,chemiluminescent labels, etc. However, there is continued interest inthe development of new labels. Of particular interest is the developmentof new protein labels, including chromo- and/or fluorescent proteinlabels.

An important new class of fluorescent proteins that have recently beendeveloped are the Reef Coral Fluorescent Proteins, as described in Matz,M. V., et al., (1999) Nature Biotechnol., 17:969-973. While thesefluorescent proteins exhibit many positive attributes, there is intenseinterest in the development of versions of this important new class offluorescent proteins that exhibit additional desirable features, e.g.,fast maturation. The present invention satisfies this need.

RELEVANT LITERATURE

U.S. patents of interest include: U.S. Pat. Nos. 6,066,476; 6,020,192;5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445;5,874,304; and 5,491,084. International Patent Publications of interestinclude: WO 00/46233; WO 99/49019; and DE 197 18 640 A. Also of interestare: Anderluh et al., Biochemical and Biophysical ResearchCommunications (1996) 220:437-442; Dove et al., Biological Bulletin(1995) 189:288-297; Fradkov et al., FEBS Lett. (2000) 479(3):127-30;Gurskaya et al., FEBS Lett., (2001) 507(1):16-20; Gurskaya et al., BMCBiochem. (2001) 2:6; Lukyanov, K., et al (2000) J Biol Chemistry275(34):25879-25882; Macek et al., Eur. J. Biochem. (1995) 234:329-335;Martynov et al., J Biol. Chem. (2001) 276:21012-6; Matz, M. V., et al.(1999) Nature Biotechnol., 17:969-973; Terskikh et al., Science (2000)290:1585-8; Tsien, Annual Rev. of Biochemistry (1998) 67:509-544; Tsien,Nat. Biotech. (1999) 17:956-957; Ward et al., J. Biol. Chem. (1979)254:781-788; Wiedermann et al., Jarhrestagung der Deutschen Gesellschactfur Tropenokologie-gto. Ulm. 17-19.02.1999. Poster P-4.20; Yarbrough etal., Proc Natl Acad Sci USA (2001) 98:462-7.

SUMMARY OF THE INVENTION

Nucleic acid compositions encoding rapidly maturing fluorescentproteins, as well as non-aggregating versions thereof (and mutantsthereof) and the proteins encoded by the same, are provided. Theproteins of interest are proteins that are fluorescent, where thisfeature arises from the interaction of two or more residues of theprotein. The subject proteins are further characterized in that, incertain embodiments, they are found in or are mutants of wild-typeproteins that are obtained from either non-bioluminescent Cnidarian,e.g., Anthozoan, species or are obtained from Anthozoannon-Pennatulacean (sea pen) species. In certain embodiments, the subjectproteins are mutants of the wild type Discosoma sp. “red” fluorescentprotein sold commercially as “DsRed”. Also of interest are proteins thatare substantially similar to, or mutants of, the above specificproteins. Also provided are fragments of the nucleic acids and thepeptides encoded thereby, as well as antibodies to the subject proteinsand transgenic cells and organisms. The subject protein and nucleic acidcompositions find use in a variety of different applications. Finally,kits for use in such applications, e.g., that include the subjectnucleic acid compositions, are provided.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Normalized excitation and emission spectra of representativeDsRed variants. (A) Mutating residue N42 alters the spectral propertiesof DsRed. Spectra are shown for DsRed1 and the N42H and N42Q variants.All three proteins were fully mature. (B) Spectra of the optimizedDsRed.T3 and DsRed.T4 variants.

FIG. 2. Maturation kinetics of DsRed variants. Logarithmically growingE. coli cultures were treated with the inducer isopropylβ-D-thiogalactopyranoside (IPTG) for 30 min to generate a pulse ofexpression for each variant. A chase was then initiated (at time 0 onthe graphs) by adding protein synthesis inhibitors and continuing the37° C. incubation. Aliquots of the cultures were removed at theindicated times and subsequently analyzed by flow cytometry to determinethe average intensity of red fluorescence per cell. The backgroundfluorescence (dashed line) was measured using cells carrying the emptypQE81 plasmid. Plotted on the two graphs are (A) the raw fluorescencevalues, or (B) the values obtained by subtracting the fluorescencepresent at time 0 and normalizing to a maximum signal of 100% for eachDsRed variant. A slight decline at later time points in the averagefluorescence values for DsRed.T3 and DsRed.T4 probably reflects celllysis. In a control culture, protein synthesis inhibitors were addedsimultaneously with IPTG to cells carrying the DsRed.T3 expressionplasmid; as expected, those cells remained nonfluorescent (data notshown). Immunoblotting indicated that during the chase period, theamount of DsRed2, DsRed.T3, and DsRed.T4 protein in the culturesremained essentially constant, whereas the amount of DsRed1 proteinprogressively declined to about half of its initial level (data notshown).

FIG. 3. Simultaneous visualization of DsRed.T4 and EGFP in yeast.DsRed.T4 was targeted to the mitochondrial matrix of Saccharomycescerevisiae by fusion to the presequence of Cox4p. The pCox4-DsRed.T4fusion protein was produced in a strain that also contained Sec7p-eGFP,a marker for Golgi cisternae. Cells from a logarithmically growingculture were imaged using either a Texas Red filter set (red) or an EGFPfilter set (green). In addition, the cells were visualized bydifferential interference contrast (DIC) microscopy. As shown in themerged image, the DsRed.T4 and EGFP signals are easily resolved. Scalebar, 2 μm.

FIG. 4. Decreasing the net charge near the N terminus of DsRed reducesaggregation of the protein. (A) Nondenaturing SDS-PAGE of purifiedDsRed1 (WT), the Round 1 variant (R1), the Round 3 variant (R3), theRound 4 variant (R4), DsRed.T1 (T1), DsRed.T3 (T3) and DsRed.T4 (T4). 1μg of each purified DsRed variant was mixed with SDS-containing samplebuffer on ice and immediately electrophoresed at 4° C. in a 10%poly-acrylamide gel, followed by staining with Coomassie Blue. WT* andT4*: Additional aliquots of DsRed1 and DsRed.T4 were denatured byboiling prior to electrophoresis. MW: broad range prestained proteinstandard (Bio-Rad). (B) To measure the solubilities of the fluorescentproteins in E. coli, cells carrying pREP4 plus pQE31-based expressionvectors encoding DsRed1, DsRed2, the Round 3 variant, the Round 4variant, or EGFP were grown to an OD₆₀₀ of 0.5, induced with IPTG for 7h, then lysed with B-PER II and centrifuged for 20 min at 27,000×g.Equivalent amounts of the pellet and supernatant fractions weresubjected to SDS-PAGE followed by immunoblotting with ananti-hexahistidine monoclonal antibody (Qiagen). The bound antibody wasdetected using the ECL-Plus kit (Amersham) and a Molecular DynamicsStorm 860 phosphorimager. For each fluorescent protein, a dilutionseries from the bacterial extract was analyzed, and a sample within thelinear range for the detection system was chosen. The percentage of eachprotein in the supernatant fraction was then quantified. Plotted are theaverage values from two separate experiments; for each fluorescentprotein, the numbers obtained in the two experiments were within 10% ofone another.

DEFINITIONS

In accordance with the present invention there may be employedconventional molecular biology, microbiology, and recombinant DNAtechniques within the skill of the art. Such techniques are explainedfully in the literature. See, e.g., Maniatis, Fritsch & Sambrook,“Molecular Cloning: A Laboratory Manual (1982); “DNA Cloning: APractical Approach,” Volumes I and II (D. N. Glover ed. 1985);“Oligonucleotide Synthesis” (M. J. Gait ed. 1984); “Nucleic AcidHybridization” (B. D. Hames & S. J. Higgins eds. (1985)); “Transcriptionand Translation” (B. D. Hames & S. J. Higgins eds. (1984)); “Animal CellCulture” (R. I. Freshney, ed. (1986)); “Immobilized Cells and Enzymes”(IRL Press, (1986)); B. Perbal, “A Practical Guide To Molecular Cloning”(1984).

A “vector” is a replicon, such as plasmid, phage or cosmid, to whichanother DNA segment may be attached so as to bring about the replicationof the attached segment.

A “DNA molecule” refers to the polymeric form of deoxyribonucleotides(adenine, guanine, thymine, or cytosine) in either single stranded formor a double-stranded helix. This term refers only to the primary andsecondary structure of the molecule, and does not limit it to anyparticular tertiary forms. Thus, this term includes double-stranded DNAfound, inter alia, in linear DNA molecules (e.g., restrictionfragments), viruses, plasmids, and chromosomes.

A DNA “coding sequence” is a DNA sequence which is transcribed andtranslated into a polypeptide in vivo when placed under the control ofappropriate regulatory sequences. The boundaries of the coding sequenceare determined by a start codon at the 5′ (amino) terminus and atranslation stop codon at the 3′ (carboxyl) terminus. A coding sequencecan include, but is not limited to, prokaryotic sequences, cDNA fromeukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian)DNA, and synthetic DNA sequences. A polyadenylation signal andtranscription termination sequence may be located 3′ to the codingsequence.

As used herein, the term “hybridization” refers to the process ofassociation of two nucleic acid strands to form an antiparallel duplexstabilized by means of hydrogen bonding between residues of the oppositenucleic acid strands.

The term “oligonucleotide” refers to a short (under 100 bases in length)nucleic acid molecule.

“DNA regulatory sequences”, as used herein, are transcriptional andtranslational control sequences, such as promoters, enhancers,polyadenylation signals, terminators, and the like, that provide forand/or regulate expression of a coding sequence in a host cell.

A “promoter sequence” is a DNA regulatory region capable of binding RNApolymerase in a cell and initiating transcription of a downstream (3′direction) coding sequence. For purposes of defining the presentinvention, the promoter sequence is bounded at its 3′ terminus by thetranscription initiation site and extends upstream (5′ direction) toinclude the minimum number of bases or elements necessary to initiatetranscription at levels detectable above background. Within the promotersequence will be found a transcription initiation site, as well asprotein binding domains responsible for the binding of RNA polymerase.Eukaryotic promoters will often, but not always, contain “TATA” boxesand “CAT” boxes. Various promoters, including inducible promoters, maybe used to drive the various vectors of the present invention.

As used herein, the terms “restriction endonucleases” and “restrictionenzymes” refer to bacterial enzymes, each of which cut double-strandedDNA at or near a specific nucleotide sequence.

A cell has been “transformed” or “transfected” by exogenous orheterologous DNA when such DNA has been introduced inside the cell. Thetransforming DNA may or may not be integrated (covalently linked) intothe genome of the cell. In prokaryotes, yeast, and mammalian cells forexample; the transforming DNA may be maintained on an episomal elementsuch as a plasmid. With respect to eukaryotic cells, a stablytransformed cell is one in which the transforming DNA has becomeintegrated into a chromosome so that it is inherited by daughter cellsthrough chromosome replication. This stability is demonstrated by theability of the eukaryotic cell to establish cell lines or clonescomprised of a population of daughter cells containing the transformingDNA. A “clone” is a population of cells derived from a single cell orcommon ancestor by mitosis. A “cell line” is a clone of a primary cellthat is capable of stable growth in vitro for many generations.

A “heterologous” region of the DNA construct is an identifiable segmentof DNA within a larger DNA molecule that is not found in associationwith the larger molecule in nature. Thus, when the heterologous regionencodes a mammalian gene, the gene will usually be flanked by DNA thatdoes not flank the mammalian genomic DNA in the genome of the sourceorganism. In another example, heterologous DNA includes coding sequencein a construct where portions of genes from two different sources havebeen brought together so as to produce a fusion protein product. Allelicvariations or naturally-occurring mutational events do not give rise toa heterologous region of DNA as defined herein.

As used herein, the term “reporter gene” refers to a coding sequenceattached to heterologous promoter or enhancer elements and whose productmay be assayed easily and quantifiably when the construct is introducedinto tissues or cells.

The amino acids described herein are preferred to be in the “L” isomericform. The amino acid sequences are given in one-letter code (A: alanine;C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; G:glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M:methionine; N: asparagine; P: proline; Q: glutamine; R: arginine; S:serine; T: threonine; V: valine; W: tryptophan; Y: tyrosine; X: anyresidue). NH₂ refers to the free amino group present at the aminoterminus of a polypeptide. COOH refers to the free carboxy group presentat the carboxy terminus of a polypeptide. In keeping with standardpolypeptide nomenclature, J. Biol. Chem., 243 (1969), 3552-59 is used.

The term “immunologically active” defines the capability of the natural,recombinant or synthetic chromo/fluorescent protein, or any oligopeptidethereof, to induce a specific immune response in appropriate animals orcells and to bind with specific antibodies. As used herein, “antigenicamino acid sequence” means an amino acid sequence that, either alone orin association with a carrier molecule, can elicit an antibody responsein a mammal. The term “specific binding,” in the context of antibodybinding to an antigen, is a term well understood in the art and refersto binding of an antibody to the antigen to which the antibody wasraised, but not other, unrelated antigens.

As used herein the term “isolated” is meant to describe apolynucleotide, a polypeptide, an antibody, or a host cell that is in anenvironment different from that in which the polynucleotide, thepolypeptide, the antibody, or the host cell naturally occurs.

Bioluminescence (BL) is defined as emission of light by living organismsthat is well visible in the dark and affects visual behavior of animals(See e.g., Harvey, E. N. (1952). Bioluminescence. New York: AcademicPress; Hastings, J. W. (1995). Bioluminescence. In: Cell Physiology (ed.by N. Speralakis). pp. 651-681. New York: Academic Press.; Wilson, T.and Hastings, J. W. (1998). Bioluminescence. Annu Rev Cell Dev Biol 14,197-230.). Bioluminescence does not include so-called ultra-weak lightemission, which can be detected in virtually all living structures usingsensitive luminometric equipment (Murphy, M. E. and Sies, H. (1990).Visible-range low-level chemiluminescence in biological systems. Meth.Enzymol. 186, 595-610; Radotic, K, Radenovic, C, Jeremic, M. (1998.)Spontaneous ultra-weak bioluminescence in plants: origin, mechanisms andproperties. Gen Physiol Biophys 17, 289-308), and from weak lightemission which most probably does not play any ecological role, such asthe glowing of bamboo growth cone (Totsune, H., Nakano, M., Inaba, H.(1993). Chemiluminescence from bamboo shoot cut. Biochem. Biophys. ResComm. 194, 1025-1029) or emission of light during fertilization ofanimal eggs (Klebanoff, S. J., Froeder, C. A., Eddy, E. M., Shapiro, B.M. (1979). Metabolic similarities between fertilization andphagocytosis. Conservation of peroxidatic mechanism. J. Exp. Med. 149,938-953; Schomer, B. and Epel, D. (1998). Redox changes duringfertilization and maturation of marine invertebrate eggs. Dev Biol 203,1-11).

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Nucleic acid compositions encoding rapidly maturing fluorescentproteins, as well as non-aggregating versions thereof (and mutantsthereof) and the proteins encoded the same, are provided. The proteinsof interest are proteins that are fluorescent, where this feature arisesfrom the interaction of two or more residues of the protein. The subjectproteins are further characterized in that, in certain embodiments, theyare mutants of wild-type proteins that are obtained either fromnon-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtainedfrom Anthozoan non-Pennatulacean (sea pen) species. In certainembodiments, the subject proteins are mutants of wild type Discosoma sp.“red” fluorescent protein. Also of interest are proteins that aresubstantially similar to, or mutants of, the above specific proteins.Also provided are fragments of the nucleic acids and the peptidesencoded thereby, as well as antibodies to the subject proteins andtransgenic cells and organisms. The subject protein and nucleic acidcompositions find use in a variety of different applications. Finally,kits for use in such applications, e.g., that include the subjectnucleic acid compositions, are provided.

Before the subject invention is described further, it is to beunderstood that the invention is not limited to the particularembodiments of the invention described below, as variations of theparticular embodiments may be made and still fall within the scope ofthe appended claims. It is also to be understood that the terminologyemployed is for the purpose of describing particular embodiments, and isnot intended to be limiting. Instead, the scope of the present inventionwill be established by the appended claims.

In this specification and the appended claims, the singular forms “a,”“an” and “the” include plural reference unless the context clearlydictates otherwise. Unless defined otherwise, all technical andscientific terms used herein have the same meaning as commonlyunderstood to one of ordinary skill in the art to which this inventionbelongs.

Where a range of values is provided, it is understood that eachintervening value, to the tenth of the unit of the lower limit unlessthe context clearly dictates otherwise, between the upper and lowerlimit of that range, and any other stated or intervening value in thatstated range, is encompassed within the invention. The upper and lowerlimits of these smaller ranges may independently be included in thesmaller ranges, and are also encompassed within the invention, subjectto any specifically excluded limit in the stated range. Where the statedrange includes one or both of the limits, ranges excluding either orboth of those included limits are also included in the invention.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood to one of ordinary skill inthe art to which this invention belongs. Although any methods, devicesand materials similar or equivalent to those described herein can beused in the practice or testing of the invention, the preferred methods,devices and materials are now described.

All publications mentioned herein are incorporated herein by referencefor the purpose of describing and disclosing the cell lines, vectors,methodologies and other invention components that are described in thepublications that might be used in connection with the presentlydescribed invention.

In further describing the subject invention, the subject nucleic acidcompositions will be described first, followed by a discussion of thesubject protein compositions, antibody compositions and transgeniccells/organisms. Next a review of representative methods in which thesubject proteins find use is provided.

Nucleic Acid Compositions

As summarized above, the subject invention provides nucleic acidcompositions encoding rapidly maturing chromo/fluoroproteins and mutantsthereof, as well as fragments and homologues of these proteins. Byrapidly maturing chromo/fluorescent protein is meant a protein that iscolored and/or fluorescent, e.g., it may exhibit low, medium or highfluorescence upon irradiation with light of an excitation wavelength.Furthermore, since the protein is rapidly maturing, it achieves itsfinal chromo/fluorescent properties in less than about 72 hours,sometimes less than 48 hours, and sometimes less than 24 hours. Incertain embodiments, the protein may mature in a period of less than 20hours, e.g., 18 hours, 16 hours, 14 hours, 12 hours, 10 hours, 8 hours,etc.

In any event, the subject proteins of interest are those in which thecolored characteristic, i.e., the chromo and/or fluorescentcharacteristic, is one that arises from the interaction of two or moreresidues of the protein, and not from a single residue, morespecifically a single side chain of a single residue, of the protein. Assuch, fluorescent proteins of the subject invention do not includeproteins that exhibit fluorescence only from residues that act bythemselves as intrinsic fluors, i.e., tryptophan, tyrosine andphenylalanine. As such, the fluorescent proteins of the subjectinvention are fluorescent proteins whose fluorescence arises from somestructure in the protein that is other than the above-specified singleresidues, e.g., it arises from an interaction of two or more residues.

By nucleic acid composition is meant a composition comprising a sequenceof DNA having an open reading frame that encodes a chromo/fluoropolypeptide of the subject invention, i.e., a chromo/fluoroprotein gene,and is capable, under appropriate conditions, of being expressed as achromo/fluoro protein according to the subject invention. Alsoencompassed in this term are nucleic acids that are homologous,substantially similar or identical to the nucleic acids of the presentinvention. Thus, the subject invention provides genes and codingsequences thereof encoding the proteins of the subject invention, aswell as homologs thereof. The subject nucleic acids, when naturallyoccurring, are present in other than their natural environment, e.g.,they are isolated, present in enriched amounts, etc., from theirnaturally occurring environment, e.g., the organism from which they areobtained.

The nucleic acids are further characterized in that, when they encodeproteins that are either from, or are mutants of proteins that are from:(1) non-bioluminescent species, often non-bioluminescent Cnidarianspecies, e.g., non-bioluminescent Anthozoan species; or (2) fromAnthozoan species that are not Pennatulacean species, i.e., that are notsea pens. As such, the nucleic acids may encode proteins that are from,or are mutants of proteins that are from, bioluminescent Anthozoanspecies, so long as these species are not Pennatulacean species, e.g.,that are not Renillan or Ptilosarcan species. Of particular interest incertain embodiments are rapidly maturing mutants of thefollowingspecific wild type proteins (or mutants thereof): (1) amFP485, cFP484,zFP506, zFP540, drFP585, dsFP484, asFP600, dgFP512, dmFP592, asdisclosed in application Ser. No. 10/006,922, the disclosure of which isherein incorporated by reference; (2) hcFP640, as disclosed inapplication Ser. No. 09/976,673, the disclosure of which is hereinincorporated by reference; (3) CgCP, as disclosed in application Ser.No. 60/255,533, the disclosure of which is herein incorporated byreference; and (4) hcriGFP, zoanRFP, scubGFP1, scubGFP2, rfloRFP,rfloGFP, mcavRFP, mcavGFP, cgigGFP, afraGFP, rfloGFP2, mcavGFP2, mannFP,as disclosed in application Ser. No. 60/332,980, the disclosure of whichis herein incorporated by reference.

In certain embodiments, the proteins encoded by the subject nucleicacids are mutants of wild type Discosoma sp. “red” fluorescent protein(drFP585), where the nucleic acid coding sequence and the amino acidsequence of this protein are disclosed in application Ser. No.10/006,922, the disclosure of which is herein incorporated by reference.Wild-Type DsRED is encoded by a nucleic acid having a sequence:

(SEQ ID NO: 01) ATGAGGTCTTCCAAGAATGTTATCAAGGAGTTCATGAGGTTTAAGGTTCGCATGGAAGGAACGGTCAATGGGCACGAGTTTGAAATAGAAGGCGAAGGAGAGGGGAGGCCATACGAAGGCCACAATACCGTAAAGCTTAAGGTAACCAAGGGGGGACCTTTGCCATTTGCTTGGGATATTTTGTCACCACAATTTCAGTATGGAAGCAAGGTATATGTCAAGCACCCTGCCGACATACCAGACTATAAAAAGCTGTCATTTCCTGAAGGATTTAAATGGGAAAGGGTCATGAACTTTGAAGACGGTGGCGTCGTTACTGTAACCCAGGATTCCAGTTTGCAGGATGGCTGTTTCATCTACAAGGTCAAGTTCATTGGCGTGAACTTTCCTTCCGATGGACCTGTTATGCAAAAGAAGACAATGGGCTGGGAAGCCAGCACTGAGCGTTTGTATCCTCGTGATGGCGTGTTGAAAGGAGAGATTCATAAGGCTCTGAAGCTGAAAGACGGTGGTCATTACCTAGTTGAATTCAAAAGTATTTACATGGCAAAGAAGCCTGTGCAGCTACCAGGGTACTACTATGTTGACTCCAAACTGGATATAACAAGCCACAACGAAGACTATACAATCGTTGAGCAGTATGAAAGAACCGAGGGACGCCACCATCTGTTCCTTTAAand has the amino acid sequence:

(SEQ ID NO: 02) MRSSKNVIKEFMRFKVRMEGTVNGHEFEIEGEGEGRPYEGHNTVKLKVTKGGPLPFAWDILSPQFQYGSKVYVKHPADIPDYKKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGCFIYKVKFIGVNFPSDGPVMQKKTMGWEASTERLYPRDGVLKGEIHKALKLKDGGHYLVEFKSIYMAKKPVQLPGYYYVDSKLDITSHNEDYTIVEQYERTEGRHHLFL

Representative rapidly maturing mutants of “DsRed” include, but are notlimited to: point mutations at position 42 relative to the startresidue, e.g., N42H, N42Q, etc.; point mutations at position 41 relativeto the start residue, e.g., H41L, H41T, etc.; point mutations atposition 44 relative to the start residue, e.g., V44A, etc.; pointmutations at position 21 relative to the start residue, e.g., T21S,etc.; and the like.

One representative nucleic acid of interest that encodes the DsRed.T1mutant described in greater detail below includes coding sequence foundin the following sequence:

(SEQ ID NO: 03) GGATCCACTAGTCGCCACC ATG GCCTCCTCCGAGGACGTCATCAAGGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCCAGTACGGCTCCAAGGTGTACGTGAAGCACCCCGCCGACATCCCCGACTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCTCCTTCATCTACAAGGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGCCCCGTAATGCAGAAGAAGACTATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAAGGGCGAGATCCACAAGGCCCTGAAGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGTGCAGCTGCCCGGCTACTACTACGTGGACTCCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAGCAGTACGAGCGCGCCGAGGGCCGCCACCACCTGTTCCTG TAG CGG CCGCwhere the bolded/underlined ATG codon is the start codon and thebold/underlined TAG is the stop codon.

In addition to the above-described fast maturing DsRed mutants,fast-maturing mutants of other species as mentioned above are also ofinterest. Such mutants or variants have point mutations such as thosedescribed above in analogous or corresponding positions of theirsequence with respect to the specific positions identified in the aboverepresentative DsRed mutants. Analogous or corresponding sequencepositions to make point mutations in a given protein are readilydetermining by aligning the enclosed specific DsRed mutants and thesequences of the wildtype protein from the species of interest withAquoria victoria green fluorescent protein, using the protocol describedin, and as illustrated in FIG. 1 of, Matz et al., Nature Biotechnology(1999) 969-973. Specific representative fast-maturing mutants of otherspecies include, but are not limited to (where the following pointpositions are numbered according to the “GFP” numbering protocolillustrated in FIG. 1 of Matz et al., supra): (1) fast maturing mutantsof dsFP483 having one or more point mutations selected from N42, e.g., Qor H, V44, e.g., A, T21, e.g., S; fast maturing mutants of zFP506 havingone or more point mutations selected from K41, e.g., L or T, 144, e.g.,A, C21, e.g., S; fast maturing mutants of aFP538 having one or morepoint mutations selected from K41, e.g., L or T, 144, e.g., A, C21,e.g., S; fast maturing mutants of amFP483 having one or more pointmutations selected from C21, e.g., S; and fast maturing mutants ofcFP484 having one or more point mutations selected from N21, e.g., S,L44, e.g. A; etc.

In addition to the above-described specific nucleic acid compositions,also of interest are homologues of the above-sequences. With respect tohomologues of the subject nucleic acids, the source of homologous genesmay be any species of plant or animal or the sequence may be wholly orpartially synthetic. In certain embodiments, sequence similarity betweenhomologues is at least about 20%, sometimes at least about 25%, and maybe 30%, 35%, 40%, 50%, 60%, 70% or higher, including 75%, 80%, 85%, 90%and 95% or higher. Sequence similarity is calculated based on areference sequence, which may be a subset of a larger sequence, such asa conserved motif, coding region, flanking region, etc. A referencesequence will usually be at least about 18 nt long, more usually atleast about 30 nt long, and may extend to the complete sequence that isbeing compared. Algorithms for sequence analysis are known in the art,such as BLAST, described in Altschul et al. (1990), J. Mol. Biol.215:403-10 (using default settings, i.e. parameters w=4 and T=17). Thesequences provided herein are essential for recognizing related andhomologous nucleic acids in database searches.

Of particular interest in certain embodiments are nucleic acids ofsubstantially the same length as the nucleic acid identified as SEQ IDNO: 01 or 02, where by substantially the same length is meant that anydifference in length does not exceed about 20 number %, usually does notexceed about 10 number % and more usually does not exceed about 5 number%; and have sequence identity to any of these sequences of at leastabout 90%, usually at least about 95% and more usually at least about99% over the entire length of the nucleic acid. In many embodiments, thenucleic acids have a sequence that is substantially similar (i.e., thesame as) or identical to the sequence of SEQ ID NO: 01 or 02. Bysubstantially similar is meant that sequence identity will generally beat least about 60%, usually at least about 75% and often at least about80, 85, 90, or even 95%.

Also provided are nucleic acids that encode the proteins encoded by theabove-described nucleic acids, but differ in sequence from theabove-described nucleic acids due to the degeneracy of the genetic code.

Also provided are nucleic acids that hybridize to the above-describednucleic acid under stringent conditions. An example of stringenthybridization conditions is hybridization at 50° C. or higher and0.1×SSC (15 mM sodium chloride/1.5 mM sodium citrate). Another exampleof stringent hybridization conditions is overnight incubation at 42° C.in a solution: 50% formamide, 5×SSC (150 mM NaCl, 15 mM trisodiumcitrate), 50 mM sodium phosphate (pH7.6), 5×Denhardt's solution, 10%dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA,followed by washing the filters in 0.1×SSC at about 65° C. Stringenthybridization conditions are hybridization conditions that are at leastas stringent as the above representative conditions, where conditionsare considered to be at least as stringent if they are at least about80% as stringent, typically at least about 90% as stringent as the abovespecific stringent conditions. Other stringent hybridization conditionsare known in the art and may also be employed to identify nucleic acidsof this particular embodiment of the invention.

Nucleic acids encoding mutants of the proteins of the invention are alsoprovided. Mutant nucleic acids can be generated by random mutagenesis ortargeted mutagenesis, using well-known techniques that are routine inthe art. In some embodiments, chromo- or fluorescent proteins encoded bynucleic acids encoding homologues or mutants have the same fluorescentproperties as the wild-type fluorescent protein. In other embodiments,homologue or mutant nucleic acids encode chromo- or fluorescent proteinswith altered spectral properties, as described in more detail herein.

One category of mutant that is of particular interest is thenon-aggregating mutant. In many embodiments, the non-aggregating mutantdiffers from the wild type sequence by a mutation in the N-terminus thatmodulates the charges appearing on side groups of the N-terminusresidues, e.g., to reverse or neutralize the charge, in a mannersufficient to produce a non-aggregating mutant of the naturallyoccurring protein or mutant, where a particular protein is considered tobe non-aggregating if it is determined be non-aggregating using theassay reported in U.S. patent application Ser. No. 10/081,864, thedisclosure of which is herein incorporated by reference, and publishedin PCT publication no. WO 02/068459.

In some embodiments, nucleic acids of this embodiment encodenon-aggregating polypeptides that exhibit reduced aggregation in vivo.“Reduced aggregation in vivo” refers to reduced aggregation in a cell.In some embodiments, the non-aggregating polypeptide shows less thanabout 90%, less than about 80%, less than about 70%, less than about60%; less than about 50%, less than about 40%, less than about 30%, lessthan about 25%, less than about 20%, less than about 15%, less thanabout 10%, or less than about 5% of the aggregation shown by itscorresponding aggregating analogue under the same in vivo conditions,e.g., in another eukaryotic cell from the same cell line, in anidentical prokaryotic cell, or in a eukaryotic cell or cell populationof the same cell type. In general, less than about 60%, less than about50%, less than about 40%, less than about 30%, less than about 20%, lessthan about 10%, or less than about 5%, of the subject non-aggregatingpolypeptide present in a cell or a cell population is aggregated.

Methods of measuring the degree of aggregation are known in the art; anyknown method can be used to determine whether a given mutant shows areduction in aggregation compared to corresponding aggregating analogue,e.g., when compared to a corresponding aggregating wild typepolypeptide. Such methods include, but are not limited to,“pseudo-native” protein gel electrophoresis; gel filtration;ultracentrifugation; circular dichroism; and light scattering.Aggregation can be measured by light scattering. For non-aggregatedproteins, the ratio of absorption at a shorter wavelength to theabsorption at a longer wavelength is close to zero. In some embodiments,the ratio of absorption at 400 nm to the absorption at 566 nm of anon-aggregating polypeptide is in the range of from about 0.01 to about0.1, from about 0.015 to about 0.09, from about 0.02 to about 0.08, fromabout 0.025 to about 0.07, or from about 0.03 to about 0.06.

In many embodiments, the nucleic acids encode non-aggregating rapidlymaturing polypeptides that have amino acid sequences that differ fromtheir corresponding wild type sequences by a mutation in the N-terminusthat modulates the charges appearing on side groups of the N-terminusresidues, e.g., to reverse or neutralize the charge, in a mannersufficient to produce a non-aggregating mutant of the naturallyoccurring protein or aggregating mutant thereof. More specifically,basic residues located near the N-termini of the proteins aresubstituted, e.g., Lys and Arg residues close to the N-terminus aresubstituted with negatively charged or neutral residues. By N-terminusis meant within about 50 residues from the N-terminus, often withinabout 25 residues of the N-terminus and more often within about 15residues of the N-terminus, where in many embodiments, residuemodifications occur within about 10 residues of the N-terminus. Specificresidues of interest in many embodiments include: 2, 3, 4, 5, 6, 7, 8, 9and 10.

Where the protein encoded by the nucleic acid is a DsRed mutant, asdescribed above, specific non-aggregating point mutations of interestinclude, but are not limited to: mutations at position 2, e.g., R2H,R2L, R2A, etc.; mutations at position 5, e.g., K5E, K5Q, K5M, etc.;mutations at position 6, e.g., N6D, etc.; and the like.

Another category of mutant of particular interest is the modulatedoligomerization mutant. A mutant is considered to be a modulatedoligomerization mutant if its oligomerization properties are differentas compared to the wild type protein. For example, if a particularmutant oligomerizes to a greater or lesser extent than the wild type, itis considered to be an oligomerization mutant. Of particular interestare oligomerization mutants that do to not oligomerize, i.e., aremonomers under physiological (e.g., intracellular) conditions, oroligomerize to a lesser extent that the wild type, e.g., are dimers ortrimers under intracellular conditions. As such, of particular interestare nucleic acids that encode monomeric versions of the subject rapidlymaturing proteins. One representative monomeric variant of the rapidlymaturing DsRed proteins described herein is the mutant named mRFP1(monomeric red fluorescent protein) and described in Campbell et al.,Proc. Natl. Acad. Sci. USA. 2002 June 11; 99 (12): 7877-7882. Thisspecific mutant contains a total of 33 mutations relative to DsRed ofwhich 13 are internal to the β-barrel (N42Q, V44A, V71A, K83L, F124L,L150M, K163M, V175A, F177V, S179T, V195T, S1971, and T217A); three arethe aggregation-reducing mutations from T1 (R2A, K5E, and N6D), threeare AB interface mutations (I125R, V1271, and 1180T), ten are ACinterface mutations (R153E, H162K, A164R, L174D, Y192A, Y194K, H222S,L223T, F224G, and L225A), and four are additional beneficial mutations(T21S, H41T, C117E, and V156A). The nucleic acid and amino acidsequences for this protein having been deposited with GENBANK andassigned an accession no. of AF506027.

Nucleic acids of the subject invention may be cDNA or genomic DNA or afragment thereof. In certain embodiments, the nucleic acids of thesubject invention include one or more of the open reading framesencoding specific fluorescent proteins and polypeptides, and introns, aswell as adjacent 5′ and 3′ non-coding nucleotide sequences involved inthe regulation of expression, up to about 20 kb beyond the codingregion, but possibly further in either direction. The subject nucleicacids may be introduced into an appropriate vector for extrachromosomalmaintenance or for integration into a host genome, as described ingreater detail below.

The term “cDNA” as used herein is intended to include all nucleic acidsthat share the arrangement of sequence elements found in native maturemRNA species, where sequence elements are exons and 5′ and 3′ non-codingregions. Normally mRNA species have contiguous exons, with theintervening introns, when present, being removed by nuclear RNAsplicing, to create a continuous open reading frame encoding theprotein.

A genomic sequence of interest comprises the nucleic acid presentbetween the initiation codon and the stop codon, as defined in thelisted sequences, including all of the introns that are normally presentin a native chromosome. It may further include 5′ and 3′ un-translatedregions found in the mature mRNA. It may further include specifictranscriptional and translational regulatory sequences, such aspromoters, enhancers, etc., including about 1 kb, but possibly more, offlanking genomic DNA at either the 5′ or 3′ end of the transcribedregion. The genomic DNA may be isolated as a fragment of 100 kbp orsmaller; and substantially free of flanking chromosomal sequence. Thegenomic DNA flanking the coding region, either 3′ or 5′, or internalregulatory sequences as sometimes found in introns, contains sequencesrequired for proper tissue and stage specific expression.

The nucleic acid compositions of the subject invention may encode all ora part of the subject proteins. Double or single stranded fragments maybe obtained from the DNA sequence by chemically synthesizingoligonucleotides in accordance with conventional methods, by restrictionenzyme digestion, by PCR amplification, etc. For the most part, DNAfragments will be of at least about 15 nt, usually at least about 18 ntor about 25 nt, and may be at least about 50 nt. In some embodiments,the subject nucleic acid molecules may be about 100 nt, about 200 nt,about 300 nt, about 400 nt, about 500 nt, about 600 nt, about 700 nt, orabout 720 nt in length. The subject nucleic acids may encode fragmentsof the subject proteins or the full-length proteins, e.g., the subjectnucleic acids may encode polypeptides of about 25 aa, about 50 aa, about75 aa, about 100 aa, about 125 aa, about 150 aa, about 200 aa, about 210aa, about 220 aa, about 230 aa, or about 240 aa, up to the entireprotein.

The subject nucleic acids are isolated and obtained in substantialpurity, generally as other than an intact chromosome. Usually, the DNAwill be obtained substantially free of other nucleic acid sequences thatdo not include a nucleic acid of the subject invention or fragmentthereof, generally being at least about 50%, usually at least about 90%pure and are typically “recombinant”, i.e. flanked by one or morenucleotides with which it is not normally associated on a naturallyoccurring chromosome.

The subject polynucleotides (e.g., a polynucleotide having a sequence ofSEQ ID NO: 01) the corresponding cDNA, the full-length gene andconstructs of the subject polynucleotides are provided. These moleculescan be generated synthetically by a number of different protocols knownto those of skill in the art. Appropriate polynucleotide constructs arepurified using standard recombinant DNA techniques as described in, forexample, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2ndEd., (1989) Cold Spring Harbor Press, Cold Spring Harbor, N.Y., andunder current regulations described in United States Dept. of HHS,National Institute of Health (NIH) Guidelines for Recombinant DNAResearch.

Also provided are nucleic acids that encode fusion proteins of thesubject proteins, or fragments thereof, which are fused to a secondprotein, e.g., a degradation sequence, a signal peptide, etc. Forexample, of interest are fusions of the present proteins with rapiddegradation sequences, such as those described in U.S. Pat. No.6,306,600 (the disclosure of which is herein incorporated by reference),the degradation domain of mouse ornithine decarboxylase (MODC), whichcontains a PEST sequence. A representative fusion protein of thisembodiment is marketed under the name “Destabilized DsRed-Express” by BDBiosciences Clontech (Palo Alto Calif.). Fusion proteins may comprise asubject polypeptide, or fragment thereof, and a non-Anthozoanpolypeptide (“the fusion partner”) fused in-frame at the N-terminusand/or C-terminus of the subject polypeptide. Fusion partners include,but are not limited to, polypeptides that can bind antibody specific tothe fusion partner (e.g., epitope tags); antibodies or binding fragmentsthereof; polypeptides that provide a catalytic function or induce acellular response; ligands or receptors or mimetics thereof; and thelike. In such fusion proteins, the fusion partner is generally notnaturally associated with the subject Anthozoan portion of the fusionprotein, and is typically not an Anthozoan protein orderivative/fragment thereof, i.e., it is not found in Anthozoan species.

Also provided are constructs comprising the subject nucleic acidsinserted into a vector, where such constructs may be used for a numberof different applications, including propagation, protein production,etc. Viral and non-viral vectors may be prepared and used, includingplasmids. The choice of vector will depend on the type of cell in whichpropagation is desired and the purpose of propagation. Certain vectorsare useful for amplifying and making large amounts of the desired DNAsequence. Other vectors are suitable for expression in cells in culture.Still other vectors are suitable for transfer and expression in cells ina whole animal or person. The choice of appropriate vector is wellwithin the skill of the art. Many such vectors are availablecommercially. To prepare the constructs, the partial or full-lengthpolynucleotide is inserted into a vector typically by means of DNAligase attachment to a cleaved restriction enzyme site in the vector.Alternatively, the desired nucleotide sequence can be inserted byhomologous recombination in vivo. Typically this is accomplished byattaching regions of homology to the vector on the flanks of the desirednucleotide sequence. Regions of homology are added by ligation ofoligonucleotides, or by polymerase chain reaction using primerscomprising both the region of homology and a portion of the desirednucleotide sequence, for example. Representative specific vectors ofinterest include, but are not limited to: pCMV-DsRed-Express Vector;pDsRED-Express Vector and pDsRed-Express-1 vector; all of which are soldby BD Biosciences Clontech (Palo Alto Calif.).

Also provided are expression cassettes or systems that find use in,among other applications, the synthesis of the subject proteins. Forexpression, the gene product encoded by a polynucleotide of theinvention is expressed in any convenient expression system, including,for example, bacterial, yeast, insect, amphibian and mammalian systems.Suitable vectors and host cells are described in U.S. Pat. No.5,654,173. In the expression vector, a subject polynucleotide, e.g., asset forth in SEQ ID NO:01 or 02, is linked to a regulatory sequence asappropriate to obtain the desired expression properties. Theseregulatory sequences can include promoters (attached either at the 5′end of the sense strand or at the 3′ end of the antisense strand),enhancers, terminators, operators, repressors, and inducers. Thepromoters can be regulated or constitutive. In some situations it may bedesirable to use conditionally active promoters, such as tissue-specificor developmental stage-specific promoters. These are linked to thedesired nucleotide sequence using the techniques described above forlinkage to vectors. Any techniques known in the art can be used. Inother words, the expression vector will provide a transcriptional andtranslational initiation region, which may be inducible or constitutive,where the coding region is operably linked under the transcriptionalcontrol of the transcriptional initiation region, and a transcriptionaland translational termination region. These control regions may benative to the subject species from which the subject nucleic acid isobtained, or may be derived from exogenous sources.

Expression vectors generally have convenient restriction sites locatednear the promoter sequence to provide for the insertion of nucleic acidsequences encoding heterologous proteins. A selectable marker operativein the expression host may be present. Expression vectors may be usedfor, among other things, the production of fusion proteins, as describedabove.

Expression cassettes may be prepared comprising a transcriptioninitiation region, the gene or fragment thereof, and a transcriptionaltermination region. Of particular interest is the use of sequences thatallow for the expression of functional epitopes or domains, usually atleast about 8 amino acids in length, more usually at least about 15amino acids in length, to about 25 amino acids, and up to the completeopen reading frame of the gene. After introduction of the DNA, the cellscontaining the construct may be selected by means of a selectablemarker, the cells expanded and then used for expression.

The above described expression systems may be employed with prokaryotesor eukaryotes in accordance with conventional ways, depending upon thepurpose for expression. For large scale production of the protein, aunicellular organism, such as E. coli, B. subtilis, S. cerevisiae,insect cells in combination with baculovirus vectors, or cells of ahigher organism such as vertebrates, e.g. COS 7 cells, HEK 293, CHO,Xenopus Oocytes, etc., may be used as the expression host cells. In somesituations, it is desirable to express the gene in eukaryotic cells,where the expressed protein will benefit from native folding andpost-translational modifications. Small peptides can also be synthesizedin the laboratory. Polypeptides that are subsets of the complete proteinsequence may be used to identify and investigate parts of the proteinimportant for function.

Specific expression systems of interest include bacterial, yeast, insectcell and mammalian cell derived expression systems. Representativesystems from each of these categories is are provided below:

Bacteria. Expression systems in bacteria include those described inChang et al., Nature (1978) 275:615; Goeddel et al., Nature (1979)281:544; Goeddel et al., Nucleic Acids Res. (1980) 8:4057; EP 0 036,776;U.S. Pat. No. 4,551,433; DeBoer et al., Proc. Natl. Acad. Sci. (USA)(1983) 80:21-25; and Siebenlist et al., Cell (1980) 20:269.

Yeast. Expression systems in yeast include those described in Hinnen etal., Proc. Natl. Acad. Sci. (USA) (1978) 75:1929; Ito et al., J.Bacteriol. (1983) 153:163; Kurtz et al., Mol. Cell. Biol. (1986) 6:142;Kunze et al., J. Basic Microbiol. (1985) 25:141; Gleeson et al., J. Gen.Microbiol. (1986) 132:3459; Roggenkamp et al., Mol. Gen. Genet. (1986)202:302; Das et al., J. Bacteriol. (1984) 158:1165; De Louvencourt etal., J. Bacteriol. (1983) 154:737; Van den Berg et al., Bio/Technology(1990) 8:135; Kunze et al., J. Basic Microbiol. (1985) 25:141; Cregg etal., Mol. Cell. Biol. (1985) 5:3376; U.S. Pat. Nos. 4,837,148 and4,929,555; Beach and Nurse, Nature (1981) 300:706; Davidow et al., Curr.Genet. (1985) 10:380; Gaillardin et al., Curr. Genet. (1985) 10:49;Ballance et al., Biochem. Biophys. Res. Commun. (1983) 112:284-289;Tilburn et al., Gene (1983) 26:205-221; Yelton et al., Proc. Natl. Acad.Sci. (USA) (1984) 81:1470-1474; Kelly and Hynes, EMBO J. (1985)4:475479; EP 0 244,234; and WO 91/00357.

Insect Cells. Expression of heterologous genes in insects isaccomplished as described in U.S. Pat. No. 4,745,051; Friesen et al.,“The Regulation of Baculovirus Gene Expression”, in: The MolecularBiology Of Baculoviruses (1986) (W. Doerfler, ed.); EP 0 127,839; EP 0155,476; and Vlak et al., J. Gen. Virot (1988) 69:765-776; Miller etal., Ann. Rev. Microbiol. (1988) 42:177; Carbonell et al., Gene (1988)73:409; Maeda et al., Nature (1985) 395:592-594; Lebacq-Verheyden etal., Mol. Cell. Biol. (1988) 8:3129; Smith et al., Proc. Natl. Acad.Sci. (USA) (1985) 82:8844; Miyajima et al., Gene (1987) 58:273; andMartin et al., DNA (1988) 7:99. Numerous baculoviral strains andvariants and corresponding permissive insect host cells from hosts aredescribed in Luckow et al., Bio/Technology (1988) 6:47-55, Miller etal., Generic Engineering (1986) 8:277-279, and Maeda et al., Nature(1985) 315:592-594.

Mammalian Cells. Mammalian expression is accomplished as described inDijkema et al., EMBO J. (1985) 4:761, Gorman et al., Proc. Natl. Acad.Sci. (USA) (1982) 79:6777, Boshart et al., Cell (1985) 41:521 and U.S.Pat. No. 4,399,216. Other features of mammalian expression arefacilitated as described in Ham and Wallace, Meth. Enz. (1979) 58:44,Barnes and Sato, Anal. Biochem. (1980) 102:255, U.S. Pat. Nos.4,767,704, 4,657,866, 4,927,762, 4,560,655, WO 90/103430, WO 87/00195,and U.S. RE 30,985.

When any of the above host cells, or other appropriate host cells ororganisms, are used to replicate and/or express the polynucleotides ornucleic acids of the invention, the resulting replicated nucleic acid,RNA, expressed protein or polypeptide, is within the scope of theinvention as a product of the host cell or organism. The product isrecovered by any appropriate means known in the art.

Once the gene corresponding to a selected polynucleotide is identified,its expression can be regulated in the cell to which the gene is native.For example, an endogenous gene of a cell can be regulated by anexogenous regulatory sequence inserted into the genome of the cell atlocation sufficient to at least enhance expressed of the gene in thecell. The regulatory sequence may be designed to integrate into thegenome via homologous recombination, as disclosed in U.S. Pat. Nos.5,641,670 and 5,733,761, the disclosures of which are hereinincorporated by reference, or may be designed to integrate into thegenome via non-homologous recombination, as described in WO 99/15650,the disclosure of which is herein incorporated by reference. As such,also encompassed in the subject invention is the production of thesubject proteins without manipulation of the encoding nucleic aciditself, but instead through integration of a regulatory sequence intothe genome of cell that already includes a gene encoding the desiredprotein, as described in the above incorporated patent documents.

Also provided are homologs of the subject nucleic acids. Homologs areidentified by any of a number of methods. A fragment of the providedcDNA may be used as a hybridization probe against a cDNA library fromthe target organism of interest, where low stringency conditions areused. The probe may be a large fragment, or one or more short degenerateprimers. Nucleic acids having sequence similarity are detected byhybridization under low stringency conditions, for example, at 50° C.and 6×SSC (0.9 M sodium chloride/0.09 M sodium citrate) and remain boundwhen subjected to washing at 55° C. in 1×SSC (0.15 M sodiumchloride/0.015 M sodium citrate). Sequence identity may be determined byhybridization under stringent conditions, for example, at 50° C. orhigher and 0.1×SSC (15 mM sodium chloride/1.5 mM sodium citrate).Nucleic acids having a region of substantial identity to the providedsequences, e.g. allelic variants, genetically altered versions of thegene, etc., bind to the provided sequences under stringent hybridizationconditions. By using probes, particularly labeled probes of DNAsequences, one can isolate homologous or related genes.

Also of interest are promoter elements of the subject genomic sequences,where the sequence of the 5′ flanking region may be utilized forpromoter elements, including enhancer binding sites, e.g., that providefor regulation of expression in cells/tissues where the subject proteinsgene are expressed.

Also provided are small DNA fragments of the subject nucleic acids,which fragments are useful as primers for PCR, hybridization screeningprobes, etc. Larger DNA fragments, i.e., greater than 100 nt are usefulfor production of the encoded polypeptide, as described in the previoussection. For use in geometric amplification reactions, such as geometricPCR, a pair of primers will be used. The exact composition of the primersequences is not critical to the invention, but for most applicationsthe primers will hybridize to the subject sequence under stringentconditions, as known in the art. It is preferable to choose a pair ofprimers that will generate an amplification product of at least about 50nt, preferably at least about 100 nt. Algorithms for the selection ofprimer sequences are generally known, and are available in commercialsoftware packages. Amplification primers hybridize to complementarystrands of DNA, and will prime towards each other.

The DNA may also be used to identify expression of the gene in abiological specimen. The manner in which one probes cells for thepresence of particular nucleotide sequences, as genomic DNA or RNA, iswell established in the literature. Briefly, DNA or mRNA is isolatedfrom a cell sample. The mRNA may be amplified by RT-PCR, using reversetranscriptase to form a complementary DNA strand, followed by polymerasechain reaction amplification using primers specific for the subject DNAsequences. Alternatively, the mRNA sample is separated by gelelectrophoresis, transferred to a suitable support, e.g. nitrocellulose,nylon, etc., and then probed with a fragment of the subject DNA as aprobe. Other techniques, such as oligonucleotide ligation assays, insitu hybridizations, and hybridization to DNA probes arrayed on a solidchip may also find use. Detection of mRNA hybridizing to the subjectsequence is indicative of Anthozoan protein gene expression in thesample.

The subject nucleic acids, including flanking promoter regions andcoding regions, may be mutated in various ways known in the art togenerate targeted changes in promoter strength, sequence of the encodedprotein, properties of the encoded protein, including fluorescentproperties of the encoded protein, etc. The DNA sequence or proteinproduct of such a mutation will usually be substantially similar to thesequences provided herein, e.g. will differ by at least one nucleotideor amino acid, respectively, and may differ by at least two but not morethan about ten nucleotides or amino acids. The sequence changes may besubstitutions, insertions, deletions, or a combination thereof.Deletions may further include larger changes, such as deletions of adomain or exon, e.g. of stretches of 10, 20, 50, 75, 100, 150 or more aaresidues. Techniques for in vitro mutagenesis of cloned genes are known.Examples of protocols for site specific mutagenesis may be found inGustin et al. (1993), Biotechniques 14:22; Barany (1985), Gene37:111-23; Colicelli et al. (1985), Mol. Gen. Genet. 199:537-9; andPrentki et al. (1984), Gene 29:303-13. Methods for site specificmutagenesis can be found in Sambrook et al., Molecular Cloning: ALaboratory Manual, CSH Press 1989, pp. 15.3-15.108; Weiner et al.(1993), Gene 126:35-41; Sayers et al. (1992), Biotechniques 13:592-6;Jones and Winistorfer (1992), Biotechniques 12:528-30; Barton at al.(1990), Nucleic Acids Res 18:7349-55; Marotti and Tomich (1989), GeneAnal. Tech. 6:67-70; and Zhu (1989), Anal Biochem 177:120-4. Suchmutated nucleic acid derivatives may be used to study structure-functionrelationships of a particular chromo/fluorescent protein, or to alterproperties of the protein that affect its function or regulation.

Also of interest are humanized versions of the subject nucleic acids. Asused herein, the term “humanized” refers to changes made to the nucleicacid sequence to optimize the codons for expression of the protein inhuman cells (Yang et al., Nucleic Acids Research 24 (1996), 4592-4593).See also U.S. Pat. No. 5,795,737 which describes humanization ofproteins, the disclosure of which is herein incorporated by reference.

Protein/Polypeptide Compositions

Also provided by the subject invention are rapidly maturing chromo-and/or fluorescent proteins and mutants thereof, as well as polypeptidecompositions related thereto. As the subject proteins arechromoproteins, they are colored proteins, which may be fluorescent, lowor non-fluorescent. As used herein, the terms chromoprotein andfluorescent protein do not include luciferases, such as Renillaluciferase, and refer to any protein that is pigmented or colored and/orfluoresces when irradiated with light, e.g., white light or light of aspecific wavelength (or narrow band of wavelengths such as an excitationwavelength). The term polypeptide composition as used herein refers toboth the full-length protein, as well as portions or fragments thereof.Also included in this term are variations of the naturally occurringprotein, where such variations are homologous or substantially similarto the naturally occurring protein, and mutants of the naturallyoccurring proteins, as described in greater detail below. The subjectpolypeptides are present in other than their natural environment.

In many embodiments, the excitation spectra of the subject proteinstypically ranges from about 300 to 700, usually from about 350 to 650and more usually from about 400 to 600 nm while the emission spectra ofthe subject proteins typically ranges from about 400 to 800, usuallyfrom about 425 to 775 and more usually from about 450 to 750 nm. Thesubject proteins generally have a maximum extinction coefficient thatranges from about 10,000 to 55,000 and usually from about 15,000 to55,000. The subject proteins typically range in length from about 150 to300 and usually from about 200 to 300 amino acid residues, and generallyhave a molecular weight ranging from about 15 to 35 kDa, usually fromabout 17.5 to 32.5 kDa.

In certain embodiments, the subject proteins are bright, where by brightis meant that the chromoproteins and their fluorescent mutants can bedetected by common methods (e.g., visual screening, spectrophotometry,spectrofluorometry, fluorescent microscopy, by FACS machines, etc.)Fluorescence brightness of particular fluorescent proteins is determinedby its quantum yield multiplied by maximal extinction coefficient.Brightness of chromoprotein may be expressed by its maximal extinctioncoefficient.

In certain embodiments, the subject proteins fold rapidly followingexpression in the host cell. By rapidly folding is meant that theproteins achieve their tertiary structure that gives rise to theirchromo- or fluorescent quality in a short period of time. In theseembodiments, the proteins fold in a period of time that generally doesnot exceed about 3 days, usually does not exceed about 2 days and moreusually does not exceed about 1 day.

Specific proteins of interest include rapidly maturing variants ofDsRed, which mature at least about 5 times more rapidly, sometimes atleast about 10 times more rapidly, e.g., at least about 15 times morerapidly or faster, than the corresponding DsRed wild type protein.Exemplary proteins of this specific embodiment include those describedin the experimental section, below, e.g., DsRed.T1; DsRed.T3; andDsRedT4.

Homologs or proteins (or fragments thereof) that vary in sequence fromthe above provided specific amino acid sequences of the subjectinvention are also provided. By homolog is meant a protein having atleast about 10%, usually at least about 20% and more usually at leastabout 30%, and in many embodiments at least about 35%, usually at leastabout 40% and more usually at least about 60% amino acid sequenceidentity to the protein of the subject invention, as determined usingMegAlign, DNAstar (1998) clustal algorithm as described in D. G. Higginsand P. M. Sharp, “Fast and Sensitive multiple Sequence Alignments on aMicrocomputer,” (1989) CABIOS, 5: 151-153. (Parameters used are ktuple1, gap penalty 3, window, 5 and diagonals saved 5). In many embodiments,homologues of interest have much higher sequence identify, e.g., 65%,70%, 75%, 80%, 85%, 90% or higher.

Also provided are proteins that are substantially identical to thespecifically described proteins herein, where by substantially identicalis meant that the protein has an amino acid sequence identity to thereference protein of at least about 60%, usually at least about 65% andmore usually at least about 70%, where in some instances the identitymay be much higher, e.g., 75%, 80%, 85%, 90%, 95% or higher.

In many embodiments, the subject homologues have structural featuresfound in the above provided specific sequences, where such structuralfeatures include the β-can fold.

Proteins that are mutants of the specifically described proteins hereinare also provided. Mutants may retain biological properties of thewild-type (e.g., naturally occurring) proteins, or may have biologicalproperties that differ from the wild-type proteins. The term “biologicalproperty” of the subject proteins includes, but is not limited to,spectral properties, such as absorbance maximum, emission maximum,maximum extinction coefficient, brightness (e.g., as compared to thewild-type protein or another reference protein such as green fluorescentprotein from A. victoria), and the like; in vivo and/or in vitrostability (e.g., half-life); etc. Mutants include single amino acidchanges, deletions of one or more amino acids, N-terminal truncations,C-terminal truncations, insertions, etc.

Mutants can be generated using standard techniques of molecular biology,e.g., random mutagenesis, and targeted mutagenesis. Several mutants aredescribed herein. Given the guidance provided in the Examples, and usingstandard techniques, those skilled in the art can readily generate awide variety of additional mutants and test whether a biologicalproperty has been altered. For example, fluorescence intensity can bemeasured using a spectrophotometer at various excitation wavelengths.

Those proteins of the subject invention that are naturally occurringproteins are present in a non-naturally occurring environment, e.g., areseparated from their naturally occurring environment. In certainembodiments, the subject proteins are present in a composition that isenriched for the subject protein as compared to its naturally occurringenvironment. For example, purified protein is provided, where bypurified is meant that the protein is present in a composition that issubstantially free of non-chromo/fluoroprotein proteins of interest,where by substantially free is meant that less than 90%, usually lessthan 60% and more usually less than 50% of the composition is made up ofnon-chromoproteins or mutants thereof of interest. The proteins of thesubject invention may also be present as an isolate, by which is meantthat the protein is substantially free of other proteins and othernaturally occurring biologic molecules, such as oligosaccharides,polynucleotides and fragments thereof, and the like, where the term“substantially free” in this instance means that less than 70%, usuallyless than 60% and more usually less than 50, % of the compositioncontaining the isolated protein is some other naturally occurringbiological molecule. In certain embodiments, the proteins are present insubstantially pure form, where by “substantially pure form” is meant atleast 95%, usually at least 97% and more usually at least 99% pure.

In addition to the specifically described proteins herein, polypeptidesthat vary from these proteins, e.g., the mutant proteins describedabove, are also provided. Generally such polypeptides include an aminoacid sequence encoded by an open reading frame (ORF) of the geneencoding the subject wild type protein, including the full lengthprotein and fragments thereof, particularly biologically activefragments and/or fragments corresponding to functional domains, and thelike; and including fusions of the subject polypeptides to otherproteins or parts thereof. Fragments of interest will typically be atleast about 10 aa in length, usually at least about 50 aa in length, andmay be as long as 300 aa in length or longer, but will usually notexceed about 1000 aa in length, where the fragment will have a stretchof amino acids that is identical to the subject protein of at leastabout 10 aa, and usually at least about 15 aa, and in many embodimentsat least about 50 aa in length. In some embodiments, the subjectpolypeptides are about 25 aa, about 50 aa, about 75 aa, about 100 aa,about 125 aa, about 150 aa, about 200 aa, about 210 aa, about 220 aa,about 230 aa, or about 240 aa in length, up to the entire protein. Insome embodiments, a protein fragment retains all or substantially all ofa biological property of the wild-type protein.

The subject proteins and polypeptides may be obtained from naturallyoccurring sources or synthetically produced. For example, wild typeproteins may be derived from biological sources which express theproteins, e.g., non-bioluminescent Cnidarian, e.g., Anthozoan, species,such as the specific ones listed above. The subject proteins may also bederived from synthetic means, e.g., by expressing a recombinant gene ornucleic acid coding sequence encoding the protein of interest in asuitable host, as described above. Any convenient protein purificationprocedures may be employed, where suitable protein purificationmethodologies are described in Guide to Protein Purification, (Deuthsered.) (Academic Press, 1990). For example, a lysate may prepared from theoriginal source and purified using HPLC, exclusion chromatography, gelelectrophoresis, affinity chromatography, and the like.

Antibody Compositions

Also provided are antibodies that specifically bind to the subjectfluorescent proteins. Suitable antibodies are obtained by immunizing ahost animal with peptides comprising all or a portion of the subjectprotein. Suitable host animals include mouse, rat sheep, goat, hamster,rabbit, etc. The origin of the protein immunogen will generally be aCnidarian species, specifically a non-bioluminescent Cnidarian species,such as an Anthozoan species or a non-Petalucean Anthozoan species. Thehost animal will generally be a different species than the immunogen,e.g., mice, etc.

The immunogen may comprise the complete protein, or fragments andderivatives thereof. Preferred immunogens comprise all or a part of theprotein, where these residues contain the post-translation modificationsfound on the native target protein. Immunogens are produced in a varietyof ways known in the art, e.g., expression of cloned genes usingconventional recombinant methods, isolation from Anthozoan species oforigin, etc.

For preparation of polyclonal antibodies, the first step is immunizationof the host animal with the target protein, where the target proteinwill preferably be in substantially pure form, comprising less thanabout 1% contaminant. The immunogen may comprise the complete targetprotein, fragments or derivatives thereof. To increase the immuneresponse of the host animal, the target protein may be combined with anadjuvant, where suitable adjuvants include alum, dextran, sulfate, largepolymeric anions, oil & water emulsions, e.g. Freund's adjuvant,Freund's complete adjuvant, and the like. The target protein may also beconjugated to synthetic carrier proteins or synthetic antigens. Avariety of hosts may be immunized to produce the polyclonal antibodies.Such hosts include rabbits, guinea pigs, rodents, e.g. mice, rats,sheep, goats, and the like. The target protein is administered to thehost, usually intradermally, with an initial dosage followed by one ormore, usually at least two, additional booster dosages. Followingimmunization, the blood from the host will be collected, followed byseparation of the serum from the blood cells. The Ig present in theresultant antiserum may be further fractionated using known methods,such as ammonium salt fractionation, DEAE chromatography, and the like.

Monoclonal antibodies are produced by conventional techniques.Generally, the spleen and/or lymph nodes of an immunized host animalprovide a source of plasma cells. The plasma cells are immortalized byfusion with myeloma cells to produce hybridoma cells. Culturesupernatant from individual hybridomas is screened using standardtechniques to identify those producing antibodies with the desiredspecificity. Suitable animals for production of monoclonal antibodies tothe human protein include mouse, rat, hamster, etc. To raise antibodiesagainst the mouse protein, the animal will generally be a hamster,guinea pig, rabbit, etc. The antibody may be purified from the hybridomacell supernatants or ascites fluid by conventional techniques, e.g.affinity chromatography using protein bound to an insoluble support,protein A sepharose, etc.

The antibody may be produced as a single chain, instead of the normalmultimeric structure. Single chain antibodies are described in Jost etal. (1994) J.B.C. 269:26267-73, and others. DNA sequences encoding thevariable region of the heavy chain and the variable region of the lightchain are ligated to a spacer encoding at least about 4 amino acids ofsmall neutral amino acids, including glycine and/or serine. The proteinencoded by this fusion allows assembly of a functional variable regionthat retains the specificity and affinity of the original antibody.

Also of interest in certain embodiments are humanized antibodies.Methods of humanizing antibodies are known in the art. The humanizedantibody may be the product of an animal having transgenic humanimmunoglobulin constant region genes (see for example InternationalPatent Applications WO 90/10077 and WO 90/04036). Alternatively, theantibody of interest may be engineered by recombinant DNA techniques tosubstitute the CH1, CH2, CH3, hinge domains, and/or the framework domainwith the corresponding human sequence (see WO 92/02190).

The use of Ig cDNA for construction of chimeric immunoglobulin genes isknown in the art (Liu et al. (1987) P.N.A.S. 84:3439 and (1987) J.Immunol. 139:3521). mRNA is isolated from a hybridoma or other cellproducing the antibody and used to produce cDNA. The cDNA of interestmay be amplified by the polymerase chain reaction using specific primers(U.S. Pat. Nos. 4,683,195 and 4,683,202). Alternatively, a library ismade and screened to isolate the sequence of interest. The DNA sequenceencoding the variable region of the antibody is then fused to humanconstant region sequences. The sequences of human constant regions genesmay be found in Kabat et al. (1991) Sequences of Proteins ofImmunological Interest, N.I.H. publication no. 91-3242. Human C regiongenes are readily available from known clones. The choice of isotypewill be guided by the desired effector functions, such as complementfixation, or activity in antibody-dependent cellular cytotoxicity.Preferred isotypes are IgG1, IgG3 and IgG4. Either of the human lightchain constant regions, kappa or lambda, may be used. The chimeric,humanized antibody is then expressed by conventional methods.

Antibody fragments, such as Fv, F(ab′)₂ and Fab may be prepared bycleavage of the intact protein, e.g. by protease or chemical cleavage.Alternatively, a truncated gene is designed. For example, a chimericgene encoding a portion of the F(ab′)₂ fragment would include DNAsequences encoding the CH1 domain and hinge region of the H chain,followed by a translational stop codon to yield the truncated molecule.

Consensus sequences of H and L J regions may be used to designoligonucleotides for use as primers to introduce useful restrictionsites into the J region for subsequent linkage of V region segments tohuman C region segments. C region cDNA can be modified by site directedmutagenesis to place a restriction site at the analogous position in thehuman sequence.

Expression vectors include plasmids, retroviruses, YACs, EBV derivedepisomes, and the like. A convenient vector is one that encodes afunctionally complete human CH or CL immunoglobulin sequence, withappropriate restriction sites engineered so that any VH or VL sequencecan be easily inserted and expressed. In such vectors, splicing usuallyoccurs between the splice donor site in the inserted J region and thesplice acceptor site preceding the human C region, and also at thesplice regions that occur within the human CH exons. Polyadenylation andtranscription termination occur at native chromosomal sites downstreamof the coding regions. The resulting chimeric antibody may be joined toany strong promoter, including retroviral LTRs, e.g. SV-40 earlypromoter, (Okayama et al. (1983) Mol. Cell. Bio. 3:280), Rous sarcomavirus LTR (Gorman et al. (1982) P.N.A.S. 79:6777), and moloney murineleukemia virus LTR (Grosschedl et al. (1985) Cell 41:885); native Igpromoters, etc.

Transgenics

The subject nucleic acids can be used to generate transgenic, non-humanplants or animals or site specific gene modifications in cell lines.Transgenic cells of the subject invention include on or more nucleicacids according to the subject invention present as a transgene, whereincluded within this definition are the parent cells transformed toinclude the transgene and the progeny thereof. In many embodiments, thetransgenic cells are cells that do not normally harbor or contain anucleic acid according to the subject invention. In those embodimentswhere the transgenic cells do naturally contain the subject nucleicacids, the nucleic acid will be present in the cell in a position otherthan its natural location, i.e. integrated into the genomic material ofthe cell at a non-natural location. Transgenic animals may be madethrough homologous recombination, where the endogenous locus is altered.Alternatively, a nucleic acid construct is randomly integrated into thegenome. Vectors for stable integration include plasmids, retrovirusesand other animal viruses, YACs, and the like.

Transgenic organisms of the subject invention include cells andmulticellular organisms, e.g., plants and animals, that are endogenousknockouts in which expression of the endogenous gene is at least reducedif not eliminated. Transgenic organisms of interest also include cellsand multicellular organisms, e.g., plants and animals, in which theprotein or variants thereof is expressed in cells or tissues where it isnot normally expressed and/or at levels not normally present in suchcells or tissues.

DNA constructs for homologous recombination will comprise at least aportion of the gene of the subject invention, wherein the gene has thedesired genetic modification(s), and includes regions of homology to thetarget locus. DNA constructs for random integration need not includeregions of homology to mediate recombination. Conveniently, markers forpositive and negative selection are included. Methods for generatingcells having targeted gene modifications through homologousrecombination are known in the art. For various techniques fortransfecting mammalian cells, see Keown et al. (1990), Meth. Enzymol.185:527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, orembryonic cells may be obtained freshly from a host, e.g. mouse, rat,guinea pig, etc. Such cells are grown on an appropriatefibroblast-feeder layer or grown in the presence of leukemia inhibitingfactor (LIF). When ES or embryonic cells have been transformed, they maybe used to produce transgenic animals. After transformation, the cellsare plated onto a feeder layer in an appropriate medium. Cellscontaining the construct may be detected by employing a selectivemedium. After sufficient time for colonies to grow, they are picked andanalyzed for the occurrence of homologous recombination or integrationof the construct. Those colonies that are positive may then be used forembryo manipulation and blastocyst injection. Blastocysts are obtainedfrom 4 to 6 week old superovulated females. The ES cells aretrypsinized, and the modified cells are injected into the blastocoel ofthe blastocyst. After injection, the blastocysts are returned to eachuterine horn of pseudopregnant females. Females are then allowed to goto term and the resulting offspring screened for the construct. Byproviding for a different phenotype of the blastocyst and thegenetically modified cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified geneand males and females having the modification are mated to producehomozygous progeny. If the gene alterations cause lethality at somepoint in development, tissues or organs can be maintained as allogeneicor congenic grafts or transplants, or in in vitro culture. Thetransgenic animals may be any non-human mammal, such as laboratoryanimals, domestic animals, etc. The transgenic animals may be used infunctional studies, drug screening, etc. Representative examples of theuse of transgenic animals include those described infra.

Transgenic plants may be produced in a similar manner. Methods ofpreparing transgenic plant cells and plants are described in U.S. Pat.Nos. 5,767,367; 5,750,870; 5,739,409; 5,689,049; 5,689,045; 5,674,731;5,656,466; 5,633,155; 5,629,470; 5,595,896; 5,576,198; 5,538,879;5,484,956; the disclosures of which are herein incorporated byreference. Methods of producing transgenic plants are also reviewed inPlant Biochemistry and Molecular Biology (eds Lea & Leegood, John Wiley& Sons)(1993) pp 275-295. In brief, a suitable plant cell or tissue isharvested, depending on the nature of the plant species. As such, incertain instances, protoplasts will be isolated, where such protoplastsmay be isolated from a variety of different plant tissues, e.g. leaf,hypoctyl, root, etc. For protoplast isolation, the harvested cells areincubated in the presence of cellulases in order to remove the cellwall, where the exact incubation conditions vary depending on the typeof plant and/or tissue from which the cell is derived. The resultantprotoplasts are then separated from the resultant cellular debris bysieving and centrifugation. Instead of using protoplasts, embryogenicexplants comprising somatic cells may be used for preparation of thetransgenic host. Following cell or tissue harvesting, exogenous DNA ofinterest is introduced into the plant cells, where a variety ofdifferent techniques are available for such introduction. With isolatedprotoplasts, the opportunity arise for introduction via DNA-mediatedgene transfer protocols, including: incubation of the protoplasts withnaked DNA, e.g. plasmids, comprising the exogenous coding sequence ofinterest in the presence of polyvalent cations, e.g. PEG or PLO; andelectroporation of the protoplasts in the presence of naked DNAcomprising the exogenous sequence of interest. Protoplasts that havesuccessfully taken up the exogenous DNA are then selected, grown into acallus, and ultimately into a transgenic plant through contact with theappropriate amounts and ratios of stimulatory factors, e.g. auxins andcytokinins. With embryogenic explants, a convenient method ofintroducing the exogenous DNA in the target somatic cells is through theuse of particle acceleration or “gene-gun” protocols. The resultantexplants are then allowed to grow into chimera plants, cross-bred andtransgenic progeny are obtained. Instead of the naked DNA approachesdescribed above, another convenient method of producing transgenicplants is Agrobacterium mediated transformation. With Agrobacteriummediated transformation, co-integrative or binary vectors comprising theexogenous DNA are prepared and then introduced into an appropriateAgrobacterium strain, e.g. A. tumefaciens. The resultant bacteria arethen incubated with prepared protoplasts or tissue explants, e.g. leafdisks, and a callus is produced. The callus is then grown underselective conditions, selected and subjected to growth media to induceroot and shoot growth to ultimately produce a transgenic plant.

Utility

The subject chromoproteins and fluorescent mutants thereof find use in avariety of different applications, where the applications necessarilydiffer depending on whether the protein is a chromoprotein or afluorescent protein. Representative uses for each of these types ofproteins will be described below, where the follow described uses aremerely representative and are in no way meant to limit the use of thesubject proteins to those described below.

Chromoproteins

The subject chromoproteins of the present invention find use in avariety of different applications. One application of interest is theuse of the subject proteins as coloring agents which are capable ofimparting color or pigment to a particular composition of matter. Ofparticular interest in certain embodiments are non-toxic chromoproteins.The subject chromoproteins may be incorporated into a variety ofdifferent compositions of matter, where representative compositions ofmatter include: food compositions, pharmaceuticals, cosmetics, livingorganisms, e.g., animals and plants, and the like. Where used as acoloring agent or pigment, a sufficient amount of the chromoprotein isincorporated into the composition of matter to impart the desired coloror pigment thereto. The chromoprotein may be incorporated into thecomposition of matter using any convenient protocol, where theparticular protocol employed will necessarily depend, at least in part,on the nature of the composition of matter to be colored. Protocols thatmay be employed include, but are not limited to: blending, diffusion,friction, spraying, injection, tattooing, and the like.

The chromoproteins may also find use as labels in analyte detectionassays, e.g., assays for biological analytes of interest. For example,the chromoproteins may be incorporated into adducts with analytespecific antibodies or binding fragments thereof and subsequentlyemployed in immunoassays for analytes of interest in a complex sample,as described in U.S. Pat. No. 4,302,536; the disclosure of which isherein incorporated by reference. Instead of antibodies or bindingfragments thereof, the subject chromoproteins or chromogenic fragmentsthereof may be conjugated to ligands that specifically bind to ananalyte of interest, or other moieties, growth factors, hormones, andthe like; as is readily apparent to those of skill in the art.

In yet other embodiments, the subject chromoproteins may be used asselectable markers in recombinant DNA applications, e.g., the productionof transgenic cells and organisms, as described above. As such, one canengineer a particular transgenic production protocol to employexpression of the subject chromoproteins as a selectable marker, eitherfor a successful or unsuccessful protocol. Thus, appearance of the colorof the subject chromoprotein in the phenotype of the transgenic organismproduced by a particular process can be used to indicate that theparticular organism successfully harbors the transgene of interest,often integrated in a manner that provides for expression of thetransgene in the organism. When used a selectable marker, a nucleic acidencoding for the subject chromoprotein can be employed in the transgenicgeneration process, where this process is described in greater detailsupra. Particular transgenic organisms of interest where the subjectproteins may be employed as selectable markers include transgenicplants, animals, bacteria, fungi, and the like.

In yet other embodiments, the chromoproteins (and fluorescent proteins)of the subject invention find use in sunscreens, as selective filters,etc., in a manner similar to the uses of the proteins described in WO00/46233.

Fluorescent Proteins

The subject fluorescent proteins of the present invention (as well asother components of the subject invention described above) find use in avariety of different applications, where such applications include, butare not limited to, the following. The first application of interest isthe use of the subject proteins in fluorescence resonance energytransfer (FRET) applications. In these applications, the subjectproteins serve as donor and/or acceptors in combination with a secondfluorescent protein or dye, e.g., a fluorescent protein as described inMatz et al., Nature Biotechnology (October 1999) 17:969-973, a greenfluorescent protein from Aequoria victoria or fluorescent mutantthereof, e.g., as described in U.S. Pat. Nos. 6,066,476; 6,020,192;5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445;5,874,304, the disclosures of which are herein incorporated byreference, other fluorescent dyes, e.g., coumarin and its derivatives,e.g. 7-amino-4-methylcoumarin, aminocoumarin, bodipy dyes, such asBodipy FL, cascade blue, fluorescein and its derivatives, e.g.fluorescein isothiocyanate, Oregon green, rhodamine dyes, e.g. texasred, tetramethylrhodamine, eosins and erythrosins, cyanine dyes, e.g.Cy3 and Cy5, macrocyclic chelates of lanthanide ions, e.g. quantum dye,etc., chemilumescent dyes, e.g., luciferases, including those describedin U.S. Pat. Nos. 5,843,746; 5,700,673; 5,674,713; 5,618,722; 5,418,155;5,330,906; 5,229,285; 5,221,623; 5,182,202; the disclosures of which areherein incorporated by reference. Specific examples of where FRET assaysemploying the subject fluorescent proteins may be used include, but arenot limited to: the detection of protein-protein interactions, e.g.,mammalian two-hybrid system, transcription factor dimerization, membraneprotein multimerization, multiprotein complex formation, etc., as abiosensor for a number of different events, where a peptide or proteincovalently links a FRET fluorescent combination including the subjectfluorescent proteins and the linking peptide or protein is, e.g., aprotease specific substrate, e.g., for caspase mediated cleavage, alinker that undergoes conformational change upon receiving a signalwhich increases or decreases FRET, e.g., PKA regulatory domain(cAMP-sensor), phosphorylation, e.g., where there is a phosphorylationsite in the linker or the linker has binding specificity tophosphorylated/dephosphorylated domain of another protein, or the linkerhas Ca²⁺ binding domain. Representative fluorescence resonance energytransfer or FRET applications in which the subject proteins find useinclude, but are not limited to, those described in: U.S. Pat. Nos.6,008,373; 5,998,146; 5,981,200; 5,945,526; 5,945,283; 5,911,952;5,869,255; 5,866,336; 5,863,727; 5,728,528; 5,707,804; 5,688,648;5,439,797; the disclosures of which are herein incorporated byreference.

The subject fluorescent proteins also find use as biosensors inprokaryotic and eukaryotic cells, e.g. as Ca²⁺ ion indicator; as pHindicator, as phorphorylation indicator, as an indicator of other ions,e.g., magnesium, sodium, potassium, chloride and halides. For example,for detection of Ca ion, proteins containing an EF-hand motif are knownto translocate from the cytosol to membranes upon Ca²⁺ binding. Theseproteins contain a myristoyl group that is buried within the molecule byhydrophobic interactions with other regions of the protein. Binding ofCa²⁺ induces a conformational change exposing the myristoyl group whichthen is available for the insertion into the lipid bilayer (called a“Ca²⁺-myristoyl switch”). Fusion of such a EF-hand containing protein toFluorescent Proteins (FP) could make it an indicator of intracellularCa²⁺ by monitoring the translocation from the cytosol to the plasmamembrane by confocal microscopy. EF-hand proteins suitable for use inthis system include, but are not limited to: recoverin (1-3),calcineurin B, troponin C, visinin, neurocalcin, calmodulin,parvalbumin, and the like. For pH, a system based on hisactophilins maybe employed. Hisactophilins are myristoylated histidine-rich proteinsknown to exist in Dictyostelium. Their binding to actin and acidiclipids is sharply pH-dependent within the range of cytoplasmic pHvariations. In living cells membrane binding seems to override theinteraction of hisactophilins with actin filaments. At pH≦6.5 theylocate to the plasma membrane and nucleus. In contrast, at pH 7.5 theyevenly distribute throughout the cytoplasmic space. This change ofdistribution is reversible and is attributed to histidine clustersexposed in loops on the surface of the molecule. The reversion ofintracellular distribution in the range of cytoplasmic pH variations isin accord with a pK of 6.5 of histidine residues. The cellulardistribution is independent of myristoylation of the protein. By fusingFPs (Fluoresent Proteins) to hisactophilin the intracellulardistribution of the fusion protein can be followed by laser scanning,confocal microscopy or standard fluorescence microscopy. Quantitativefluorescence analysis can be done by performing line scans through cells(laser scanning confocal microscopy) or other electronic data analysis(e.g., using metamorph software (Universal Imaging Corp) and averagingof data collected in a population of cells. Substantial pH-dependentredistribution of hisactophilin-FP from the cytosol to the plasmamembrane occurs within 1-2 min and reaches a steady state level after5-10 min. The reverse reaction takes place on a similar time scale. Assuch, hisactophilin-fluorescent protein fusion protein that acts in ananalogous fashion can be used to monitor cytosolic pH changes in realtime in live mammalian cells. Such methods have use in high throuhgputapplications, e.g., in the measurement of pH changes as consequence ofgrowth factor receptor activation (e.g. epithelial or platelet-derivedgrowth factor) chemotactic stimulation/cell locomotion, in the detectionof intracellular pH changes as second messenger, in the monitoring ofintracellular pH in pH manipulating experiments, and the like. Fordetection of PKC activity, the reporter system exploits the fact that amolecule called MARCKS (myristoylated alanine-rich C kinase substrate)is a PKC substrate. It is anchored to the plasma membrane viamyristoylation and a stretch of positively charged amino acids(ED-domain) that bind to the negatively charged plasma membrane viaelectrostatic interactions. Upon PKC activation the ED-domain becomesphosphorylated by PKC, thereby becoming negatively charged, and as aconsequence of electrostatic repulsion MARCKS translocates from theplasma membrane to the cytoplasm (called the “myristoyl-electrostaticswitch”). Fusion of the N-terminus of MARCKS ranging from themyristoylation motif to the ED-domain of MARCKS to fluorescent proteinsof the present invention makes the above a detector system for PKCactivity. When phosphorylated by PKC, the fusion protein translocatesfrom the plasma membrane to the cytosol. This translocation is followedby standard fluorescence microscopy or confocal microscopy e.g. usingthe Cellomics technology or other High Content Screening systems (e.g.Universal Imaging Corp./Becton Dickinson). The above reporter system hasapplication in High Content Screening, e.g., screening for PKCinhibitors, and as an indicator for PKC activity in many screeningscenarios for potential reagents interfering with this signaltransduction pathway. Methods of using fluorescent proteins asbiosensors also include those described in U.S. Pat. Nos. 972,638;5,824,485 and 5,650,135 (as well as the references cited therein) thedisclosures of which are herein incorporated by reference.

The subject fluorescent proteins also find use in applications involvingthe automated screening of arrays of cells expressing fluorescentreporting groups by using microscopic imaging and electronic analysis.Screening can be used for drug discovery and in the field of functionalgenomics: e.g., where the subject proteins are used as markers of wholecells to detect changes in multicellular reorganization and migration,e.g., formation of multicellular tubules (blood vessel formation) byendothelial cells, migration of cells through Fluoroblok Insert System(Becton Dickinson Co.), wound healing, neurite outgrowth, etc.; wherethe proteins are used as markers fused to peptides (e.g., targetingsequences) and proteins that allow the detection of change ofintracellular location as indicator for cellular activity, for example:signal transduction, such as kinase and transcription factortranslocation upon stimuli, such as protein kinase C, protein kinase A,transcription factor NFkB, and NFAT; cell cycle proteins, such as cyclinA, cyclin B1 and cyclinE; protease cleavage with subsequent movement ofcleaved substrate, phospholipids, with markers for intracellularstructures such as endoplasmic reticulum, Golgi apparatus, mitochondria,peroxisomes, nucleus, nucleoli, plasma membrane, histones, endosomes,lysosomes, microtubules, actin) as tools for High Content Screening:co-localization of other fluorescent fusion proteins with theselocalization markers as indicators of movements of intracellularfluorescent fusion proteins/peptides or as marker alone; and the like.Examples of applications involving the automated screening of arrays ofcells in which the subject fluorescent proteins find use include: U.S.Pat. No. 5,989,835; as well as WO/0017624; WO 00/26408; WO 00/17643; andWO 00/03246; the disclosures of which are herein incorporated byreference.

The subject fluorescent proteins also find use in high through-putscreening assays. The subject fluorescent proteins are stable proteinswith half-lives of more than 24 h. Also provided are destabilizedversions of the subject fluorescent proteins with shorter half-livesthat can be used as transcription reporters for drug discovery. Forexample, a protein according to the subject invention can be fused witha putative proteolytic signal sequence derived from a protein withshorter half-life, e.g., PEST sequence from the mouse ornithinedecarboxylase gene, mouse cyclin B1 destruction box and ubiquitin, etc.For a description of destabilized proteins and vectors that can beemployed to produce the same, see e.g., U.S. Pat. No. 6,130,313; thedisclosure of which is herein incorporated by reference. Promoters insignal transduction pathways can be detected using destabilized versionsof the subject fluorescent proteins for drug screening, e.g., AP1, NFAT,NFkB, Smad, STAT, p53, E2F, Rb, myc, CRE, ER, GR and TRE, and the like.

The subject proteins can be used as second messenger detectors, e.g., byfusing the subject proteins to specific domains: e.g., PKCgamma Cabinding domain, PKCgamma DAG binding domain, SH2 domain and SH3 domain,etc.

Secreted forms of the subject proteins can be prepared, e.g. by fusingsecreted leading sequences to the subject proteins to construct secretedforms of the subject proteins, which in turn can be used in a variety ofdifferent applications.

The subject proteins also find use in fluorescence activated cellsorting applications. In such applications, the subject fluorescentprotein is used as a label to mark a population of cells and theresulting labeled population of cells is then sorted with a fluorescentactivated cell sorting device, as is known in the art. FACS methods aredescribed in U.S. Pat. Nos. 5,968,738 and 5,804,387; the disclosures ofwhich are herein incorporated by reference.

The subject proteins also find use as in vivo marker in animals (e.g.,transgenic animals). For example, expression of the subject protein canbe driven by tissue specific promoters, where such methods find use inresearch for gene therapy, e.g., testing efficiency of transgenicexpression, among other applications. A representative application offluorescent proteins in transgenic animals that illustrates this classof applications of the subject proteins is found in WO 00/02997, thedisclosure of which is herein incorporated by reference.

Additional applications of the subject proteins include: as markersfollowing injection into cells or animals and in calibration forquantitative measurements (fluorescence and protein); as markers orreporters in oxygen biosensor devices for monitoring cell viability; asmarkers or labels for animals, pets, toys, food, etc.; and the like.

The subject fluorescent proteins also find use in protease cleavageassays. For example, cleavage inactivated fluorescence assays can bedeveloped using the subject proteins, where the subject proteins areengineered to include a protease specific cleavage sequence withoutdestroying the fluorescent character of the protein. Upon cleavage ofthe fluorescent protein by an activated protease fluorescence wouldsharply decrease due to the destruction of a functional chromophor.Alternatively, cleavage activated fluorescence can be developed usingthe subject proteins, where the subject proteins are engineered tocontain an additional spacer sequence in close proximity/or inside thechromophor. This variant would be significantly decreased in itsfluorescent activity, because parts of the functional chromophor wouldbe divided by the spacer. The spacer would be framed by two identicalprotease specific cleavage sites. Upon cleavage via the activatedprotease the spacer would be cut out and the two residual “subunits” ofthe fluorescent protein would be able to reassemble to generate afunctional fluorescent protein. Both of the above types of applicationcould be developed in assays for a variety of different types ofproteases, e.g., caspases, etc.

The subject proteins can also be used is assays to determine thephospholipid composition in biological membranes. For example, fusionproteins of the subject proteins (or any other kind of covalent ornon-covalent modification of the subject proteins) that allows bindingto specific phospholipids to localize/visualize patterns of phospholipiddistribution in biological membranes also allowing colocalization ofmembrane proteins in specific phospholipid rafts can be accomplishedwith the subject proteins. For example, the PH domain of GRP1 has a highaffinity to phosphatidyl-inositol tri-phosphate (PIP3) but not to PIP2.As such, a fusion protein between the PH domain of GRP1 and the subjectproteins can be constructed to specifically label PIP3 rich areas inbiological membranes.

Yet another application of the subject proteins is as a fluorescenttimer, in which the switch of one fluorescent color to another (e.g.green to red) concomitant with the ageing of the fluorescent protein isused to determine the activation/deactivation of gene expression, e.g.,developmental gene expression, cell cycle dependent gene expression,circadian rhythm specific gene expression, and the like

The antibodies of the subject invention, described above, also find usein a number of applications, including the differentiation of thesubject proteins from other fluorescent proteins.

Kits

Also provided by the subject invention are kits for use in practicingone or more of the above described applications, where the subject kitstypically include elements for making the subject proteins, e.g., aconstruct comprising a vector that includes a coding region for thesubject protein. The subject kit components are typically present in asuitable storage medium, e.g., buffered solution, typically in asuitable container. Also present in the subject kits may be antibodiesto the provided protein. In certain embodiments, the kit comprises aplurality of different vectors each encoding the subject protein, wherethe vectors are designed for expression in different environments and/orunder different conditions, e.g., constitutive expression where thevector includes a strong promoter for expression in mammalian cells, apromoterless vector with a multiple cloning site for custom insertion ofa promoter and tailored expression, etc.

In addition to the above components, the subject kits will furtherinclude instructions for practicing the subject methods. Theseinstructions may be present in the subject kits in a variety of forms,one or more of which may be present in the kit. One form in which theseinstructions may be present is as printed information on a suitablemedium or substrate, e.g., a piece or pieces of paper on which theinformation is printed, in the packaging of the kit, in a packageinsert, etc. Yet another means would be a computer readable medium,e.g., diskette, CD, etc., on which the information has been recorded.Yet another means that may be present is a website address which may beused via the internet to access the information at a removed site. Anyconvenient means may be present in the kits.

The following examples are offered by way of illustration and not by wayof limitation.

EXPERIMENTAL I. Introduction

The red fluorescent protein DsRed has spectral properties that are idealfor dual-color experiments with green fluorescent protein (GFP). Butwild-type DsRed has several drawbacks, including slow chromophorematuration and poor solubility. To overcome the slow maturation, we usedrandom and directed mutagenesis to create DsRed variants that mature10-15 times faster than the wild-type protein. Anasparagine-to-glutamine substitution at position 42 greatly acceleratesthe maturation of DsRed, but also increases the level of green emission.Additional amino acid substitutions suppress this green emission whilefurther accelerating the maturation. To enhance the solubility of DsRed,the net charge near the N terminus of the protein was reduced. Theresultant DsRed variants yield bright fluorescence even in rapidlygrowing organisms such as yeast.

II. Experimental Protocol A. Mutagenesis and Screening.

For mutagenesis, a wild-type or mutant DsRed gene present in thepDsRed1-N1 vector (Clontech, Palo Alto, Calif.) was excised with NheIand HpaI and used as a template for error-prone PCR (Cadwell, R. C. &Joyce, G. F. In PCR Primer. A laboratory manual. (eds Dieffenbach, C. W.& Dveksler, G. S.) 583-589 (Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y.; 1995)). The amplified product was digested withBamHI and BsaBI, gel purified, and ligated between the BamHI andEcI13611 sites of the pQE31 expression vector (Qiagen, Valencia,Calif.), which encodes an N-terminal hexahistidine tag. The library ofmutated DsRed genes was transformed into E. coli strain DH10B. Forrounds 1-3 of the mutagenesis, 50,000-100,000 colonies were screened forbright fluorescence using the slide projector assay described in thetext. For round 4, 4,000 brightly fluorescent colonies were picked intowells of 96-well plates, then grown to saturation, lysed with B-PER IIreagent (Pierce, Rockford, Ill.), and centrifuged for 5 min at 2,500 g.The supernatants were transferred to a second set of 96-well plates, andthe fluorescence signals from the pellets and supernatants were comparedvisually using the slide projector assay. Clones that showed an elevatedratio of soluble to insoluble fluorescence were analyzed further. Forround 5, 10 pools of 10,000 mutant clones each were recovered from thetransformation plates and subjected to cell sorting using a BectonDickinson FACStarPlus flow cytometer. Fluorescence signals were measuredsimultaneously in the green (FL-1) and red (FL-2) channels, and cellswere collected if they showed strong red fluorescence but reduced greenfluorescence.

B. Purification and Spectral Analysis of the DsRed Variants

To purify the hexa-histidine-tagged proteins, a fluorescent protein genein the pQE31 vector was transformed into E. coli cells carrying thepREP4 repressor plasmid (Qiagen). A 250 ml culture was grown to an OD600of 0.5 and then induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG)for 6-8 h at 37° C. The cells were lysed with 10 ml of B-PER II andcentrifuged for 20 min at 27,000 g. Detergent was removed from thesupernatant by adding NaCl to 300 mM and centrifuging for 10 min at2,500 g. After adding 1 ml of Ni²⁺-NTA-agarose beads (Qiagen), the tubewas mixed end-over-end for 1 h. The beads were washed three times with10 ml of 300 mM NaCl, 20 mM imidazole-HCl, pH 7.4, 0.5% Triton X-100,and then three times with the same buffer lacking Triton X-100. Thefluorescent protein was eluted with 2.5 ml of 300 mM imidazole-HCl, pH7.4, and dialyzed into 50 mM Na⁺-HEPES, pH 7.5, 100 mM NaCl, 1 mM EDTA.

Corrected excitation and emission spectra of purified DsRed variants,diluted to an A558 of <0.04 in Na⁺-HEPES, pH 7.5, 100 mM NaCl, 1 mMEDTA, were acquired with a Horiba FluoroMax-3 spectrofluorometer. Thescanning windows were 1 nM. Emission was measured at 600 nm for theexcitation spectra, and excitation was at 470 nm for the emissionspectra. To determine extinction coefficients, the fluorescent proteinconcentrations were assayed using the BCA method (Pierce), and theabsorbances of the proteins at their excitation maxima were measuredusing a Spectronic Unicam GENESYS 10 UV spectrophotometer. Quantumyields were determined as described (Baird, et al., Proc. Natl. Acad.Sci. USA 97, 11984-11989 (2000); Lakowicz, J. R. Principles offluorescence spectroscopy, Edn. 2. (Kluwer Academic/Plenum Publishers,New York, N.Y.; 1999)) using ethanolic rhodamine 101 as a reference; forthese measurements the excitation wavelength was 535 nm and thefluorescence emission as integrated from 550-800 nm.

C. Measurement of Maturation Kinetics

Genes encoding the DsRed variants were cloned into the pQE81 expressionvector (Qiagen) and transformed into E. coli. Bacterial cultures growingwith aeration at 37° C. were induced with 1 mM IPTG for 30 min togenerate a pulse of expression for each DsRed variant. A chase was theninitiated by inhibiting protein synthesis with a mixture of 170 μg/mlchloramphenicol, 30 μg/ml kanamycin, and 50 μg/ml tetracycline. At thedesignated time points, aliquots of the cultures were removed, adjustedto 15% glycerol, and frozen at −80° C. These aliquots were later thawedrapidly and evaluated using a Becton Dickinson FACScan flow cytometer todetermine the average intensity of red fluorescence (channel FL-2) percell. A portion of each aliquot was precipitated with trichloroaceticacid, then subjected to SDS—PAGE and immunoblotting with ananti-hexahistidine monoclonal antibody (Qiagen) to measure the totalamount of DsRed polypeptide in the cultures. Fluorescence microscopy ofyeast. A CEN plasmid derived from pRS315 (Sikorski, Genetics 122, 19-27(1989)) and carrying a pCox4-DsRed1 fusion gene under the control of theADH1 promoter was used. Derivatives of this plasmid were created byreplacing the DsRed1 coding sequence with the coding sequence ofDsRed.T3 or DsRed.T4. These plasmids were introduced into S. cerevisiaestrain BGY101, which carries a chromosomal SEC7-EGFPx3 gene 20. Cellsfrom the resulting yeast strains were grown in minimal glucose mediumand fixed, and projected fluorescence images were acquired as describedRossanese et al., J. Cell Biol. 145, 69-81 (1999).

III. Results and Discussion

A family of fluorescent proteins has recently been described. The mostuseful of these newly discovered proteins is DsRed, which is derivedfrom the coral Discosoma. DsRed has an orange-red fluorescence with anemission maximum at 583 nm. Biophysical and X-ray crystallographicstudies revealed that DsRed forms a stable tetramer, and that eachmonomer is structurally very similar to GFP. The red-shiftedfluorescence of DsRed relative to GFP results from a chromophore with amore extensive conjugated π-system. DsRed fluorescence is excitedoptimally at 558 nm, but can also be excited by a standard 488 nm laser,allowing DsRed to be used with laser-based confocal micro-scopes andflow cytometers. DsRed has a high quantum yield and is photostable.These characteristics make DsRed an ideal candidate for fluorescenceimaging, particularly for multicolor experiments involving GFP and itsvariants. A codon-optimized version of DsRed is now available under thename DsRed1.

Despite these advantages, wild-type DsRed has several problems for useas a fluorescent reporter. When DsRed is fused to another protein,tetramerization of the DsRed domain can perturb the function andlocalization of the protein. The DsRed tetramer also self-associates toform higher-order aggregates. Perhaps the most serious problem withDsRed is that chromophore maturation is slow, with a half-time of >24 hat room temperature. Newly synthesized DsRed develops a dim greenfluorescence by forming the same chromophore that is present in GFP. Asecond oxidation reaction then generates the red chromophore. This slowmaturation has been put to use with a DsRed variant termed the“fluorescent timer”, in which the fluorescence of the initial greenspecies is enhanced. However, for most applications the slow maturationof DsRed is not desirable. In dual-label imaging with GFP, the initialgreen fluorescence of DsRed produces bleed-through into the GFP channel.More generally, the slow development of red fluorescence limits theintensity of the DsRed signal, particularly with rapidly growingorganisms such as yeast. A variant termed DsRed2 matures faster thanDsRed1, but DsRed2 still requires many hours to attain fullfluorescence. Here random and directed mutagenesis was used to createimproved variants of DsRed. These new variants mature rapidly, and theyare more soluble than wild-type DsRed.

To identify rapidly maturing DsRed variants, an earlier method forvisualizing GFP fluorescence in microbial colonies was modified.Hexahistidine-tagged DsRed is produced at high levels in Escherichiacoli. The fluorescence of the bacterial colonies is excited by placing a520±20 nm bandpass filter over the lens of a slide projector, and theemission is detected through goggles covered with a Kodak Wratten filterno. 22, which passes wavelengths >550 nm. This technique is simple andefficient.

A library of mutant expression plasmids was generated using error-pronePCR to amplify the DsRed1 template. This library was transformed into E.coli, and over 100,000 transformant colonies were examined. Coloniesproducing the wild-type DsRed1 protein required two days to developsignificant fluorescence, but three mutant colonies showed strongfluorescence after one day of growth. Sequencing revealed that the threemutant plasmids were distinct, but that all of them contained an N42Hcodon change. We therefore generated a variant that had only the N42Hsubstitution.

The N42H variant was purified in parallel with DsRed1, and the twoproteins were analyzed by spectrofluorometry. As previously observed,the spectra of purified DsRed1 changed over a period of days as theprotein matured (data not shown). By contrast, the spectra of thepurified N42H variant remained stable over time (data not shown),consistent with rapid maturation. Unfortunately, in addition toaccelerating maturation, the N42H substitution altered the spectralproperties of the mature protein (FIG. 1A). Mature DsRed1 is thought tobe an equilibrium mixture of red fluorescent molecules and some greenfluorescent molecules that are spectrally similar to GFP. The GFP-likespecies has a blue excitation peak at approximately 480 nm and a greenemission peak at approximately 500 nm; but DsRed is a tetramer, soexcitation of the green molecules often results in fluorescenceresonance energy transfer (FRET) with neighboring red molecules toproduce red emission. This FRET effect, together with the relatively lowpercentage of green molecules in mature DsRed1, yields a very small peakof green emission relative to the red emission (FIG. 1A). In the N42Hvariant, the peaks of blue excitation and green emission weredramatically enhanced (FIG. 1A), indicating that the equilibrium hadshifted so that a larger percentage of the mature molecules containedthe green chromophore.

Because the N42H substitution considerably increases the size of theside chain, a more conservative N42Q substitution was also tried. Thismutation required two base changes and probably would not have beenpresent in the original mutant collection. The N42Q variant retained therapid maturation property of the N42H variant, but showed much less blueexcitation and green emission (FIG. 1A). The N42Q variant was thereforechosen as the starting point for further study.

Additional mutagenesis (see below) yielded DsRed variants that showedeven faster maturation and lower green emission than the original N42Qvariant. After six rounds of mutagenesis, three optimized variants wereselected and termed DsRed.T1, DsRed.T3, and DsRed.T4 (Table 1). Thespectral properties of DsRed.T4 (FIG. 1B) are virtually identical tothose of DsRed.T1 (data not shown) and very similar to those of thewild-type DsRed1 (FIG. 1A). Compared with DsRed.T1 and DsRed.T4,DsRed.T3 is somewhat brighter (see below) but has a significantly higherpeak of blue excitation and a marginally higher peak of green emission(FIG. 1B).

The optimized DsRed variants were examined both in vivo and in vitro. Asjudged by colony fluorescence, colony size, and plasmid stability, thesevariants were less toxic to E. coli than DsRed1, and they developedfluorescence more efficiently at growth temperatures of 37° C. andhigher (data not shown). Like wild-type DsRed, the optimized variantsappeared to be tetrameric: they exhibited FRET between the green and redmolecules (FIG. 1B), and upon nondenaturing SDS-PAGE they migrated atthe position expected for tetramers (see below). With purified DsRed1,we measured an extinction coefficient of 52,000 M-1 cm-1 and a quantumyield of approximately 0.7 (Table 1).

TABLE 1 Properties of the mature DsRed variants^(a) Excita- Emis- Matu-tion sion Maximal Rela- ration maxi- maxi- extinction Quan- tive half-DsRed mum mum coefficient tum bright- time variant (nm) (nm) (M⁻¹ cm⁻¹)yield ness^(b) (h)^(c) DsRed 558 583 52,000 0.68 (1.00) 11 1 DsRed 561587 43,800 0.55 0.68 6.5 2 DsRed. 554 586 30,100 0.42 0.36 0.70 T1DsRed. 560 587 49,500 0.59 0.83 1.3 T3 DsRed. 555 586 30,300 0.44 0.380.71 T4 ^(a)“Relative to wild-type DsRed, the other variants contain thefollowing substitutions, where P(−4)L indicates a codon change in thepolylinker upstream of the start codon.” DsRed2: R2A, K5E, K9T, V105A,I161T, S197A. DsRed. T1: P(−4)L, R2A, K5E, N6D, T21S, H41T, N42Q, V44A,C117S, T217A. DsRed. T3: P(−4)L, R2A, K5E, N6D, T21S, H41T, N42Q, V44A,A145P. DsRed. T4: P(−4)L, R2A, K5E, N6D, T21S, H41T, N42Q, V44A, A145P,T217A. ^(b)Brightness is determined by the product of the extinctioncoefficient and the quantum yield. Relative brightness is calculated bydefining the brightness of DsRed1 as 1.00. ^(c)The half-times formaturation were estimated graphically using the experimental protocol ofFIG. 2. Values listed are the averages from two separate experiments;for each DsRed variant, the numbers obtained in the two experiments werewithin 15% of one another.

A previous study of wild-type DsRed reported a similar quantum yield buta higher extinction coefficient of 75,000 M⁻¹ cm⁻¹; the reason for thisdiscrepancy is unclear. DsRed2 shows slight reductions in bothextinction coefficient and quantum yield, resulting in a relativebrightness of 0.68 compared to DsRed1 (Table 1). DsRed.T3 is nearly asbright as DsRed1. However, DsRed.T1 and DsRed.T4 are dimmer, withrelative brightnesses of 0.36-0.38 compared to DsRed1. To quantify thematuration kinetics of the DsRed variants, an in vivo pulse-chaseanalysis with E. coli cultures growing at 37° C. (FIG. 2) was performed.After a 30 min pulse of induction, protein synthesis inhibitors wereadded, and samples of the cultures were taken at various chase times.The average cellular fluorescence for each sample was measured by flowcytometry using a 488 nm excitation laser.

FIG. 2A shows the raw data, while FIG. 2B shows the data normalized to amaximal fluorescence of 100%. Under these conditions, DsRed1 matureswith a half-time of approximately 11 h, although accurate measurementsare difficult with DsRed1 because the fluorescence values do not reach aplateau (FIG. 2) and because some of the DsRed1 protein is degradedduring the chase period (data not shown). DsRed2 matures somewhatfaster, with a half-time of approximately 6.5 h. The rates offluorescence acquisition for DsRed1 and DsRed2 increase after apro-nounced lag phase, indicating that multiple slow steps are involved.DsRed.T3 matures with a brief lag phase and half-time of approximately1.3 h.

DsRed.T4 and DsRed.T1 mature with no detectable lag phase and withhalf-times of 0.7 h, about 15-fold faster than DsRed1 (FIG. 2, and datanot shown). With this pulse-chase protocol, the different DsRed variantsreproducibly showed distinct plateau values of average cellularfluorescence (FIG. 2A). The highsignal from DsRed.T3 can be explained bythe relatively strong excitation of this protein at 488 nm (see FIG.1B). DsRed1, DsRed2, and DsRed.T4 all have similar fluorescence spectra,yet the plateau fluorescence of DsRed.T4-expressing cells is 4-foldhigher than that of DsRed1-expressing cells and 10-fold higher than thatof DsRed2-expressing cells. This result is surprising because purifieddsRed.T4 is less bright than DsRed1 or DsRed2 (Table 1). We speculatethat immature DsRed1 is unstable in E. coli, and that this problem isexacerbated with DsRed2, so that a large fraction of the newlysynthesized DsRed1 and DsRed2 molecules are lost through aggregationand/or degradation. Consistent with this idea, a previous study reportedthat most of the newly synthesized DsRed1 molecules are degraded in E.coli or Drosophila cells. Interestingly, DsRed2 gives a brighterfluorescence signal than DsRed1 in mammalian cells suggesting that theefficiency of expression for a given DsRed variant may be cell typespecific.

The benefits of accelerated maturation should be particularly evidentwhen the DsRed variants are produced in a rapidly growing organism. Totest this prediction, we targeted different DsRed variants to yeastmitochondria. The parental yeast strain also contained an EGFP-taggedmarker for Golgi cisternae. With mitochondrially targeted DsRed1, thefluorescence was extremely faint in cells from growing cultures, andonly became readily visible in a subset of the cells once the culturesreached stationary phase (data not shown). By contrast, mitochondriallytargeted DsRed.T4 consistently gave a strong fluorescence signal incells from growing cultures (FIG. 3). As shown in the merged image, weobserved no detectable bleed-through of DsRed.T4 fluorescence into thegreen channel or of EGFP fluorescence into the red channel. Similarresults were obtained with mitochondrially targeted DsRed.T3 (data notshown). However, with other fusion constructs we found that when a largeamount of DsRed.T3 was concentrated in a small region of the cell, somebleed-through occurred into the green channel (not shown). Therefore,DsRed.T4 is the protein of choice for obtaining a clean separation ofred and green fluorescence signals.

These results confirm that random mutagenesis followed by screening is apowerful method for creating improved fluorescent proteins. Our keyfinding is that Asn42 substitutions such as N42Q dramatically acceleratechromophore formation.

A side effect of Asn42 substitutions is a pronounced increase in blueexcitation and green emission (FIG. 1A). Mature wild-type DsRed appearsto be an equilibrium mixture of a red species and a green species, andthe Asn42 substitutions evidently shift the equilibrium to yield ahigher percentage of the green species. By introducing a series ofadditional substitutions into the N42Q background, we could suppressnearly all of the blue excitation and green emission that were conferredby N42Q while preserving the rapid maturation (FIG. 1 and Table 1).

Another improvement over wild-type DsRed was achieved by decreasing thenet charge near the N terminus. The resulting DsRed variants showreduced aggregation in vitro (see below) and in vivo. Wild-type DsRed isunusually basic, with a predicted pI of 8.0, and probably associatesnonspecifically with anionic cellular components. In addition, basicpatches on the surface of a DsRed tetramer may interact with acidicpatches on a second tetramer to cause higher-order aggregation. Thisinteraction of DsRed with other macromolecules is evidently reduced byeliminating the cluster of positive charges near the N terminus.

The end result of our work is a pair of optimized variants termedDsRed.T3 and DsRed.T4. DsRed.T3 matures rapidly, and the purifiedprotein is nearly as bright as mature wild-type DsRed (Table 1), makingthis variant well suited to single-color imaging of red fluo-rescence.DsRed.T3 has a higher peak of blue excitation and a slightly higher peakof green emission than wild-type DsRed (FIG. 1B), resulting in somecontamination of the GFP signal in dual-color experiments. However, thiscontamination is usually minor. The enhanced blue excitation of DsRed.T3can actually be advantageous, for example, if the fluorescence is beingexcited by a 488 nm laser (FIG. 2). DsRed.T4 has fluorescence spectravery similar to those of wild-type DsRed (FIG. 1B) and yields negligiblecontamination of the GFP signal (FIG. 3). Although purified DsRed.T4 isonly about half as bright as DsRed.T3, this effect is partially offsetin vivo because DsRed.T4 matures nearly twice as fast as DsRed.T3 (Table1). Thus, DsRed.T4 is probably the best variant for most applications.DsRed.T1 is essentially identical to DsRed.T4 (Table 1), except thatDsRed.T1 lacks cysteine residues and therefore might fold moreefficiently in the oxidizing environment of the secretory pathway.

DsRed.T4 is a suitable template for further mutagenesis to produceadditional variants.

The generation of new DsRed variants is likely to involve both randomand directed mutagenesis. For directed mutagenesis studies, it is worthnoting that five of the substitutions present in DsRed.T4 (R2A, H41T,N42Q, A145P, and T217A) replace a given residue with a residue that ismore generally conserved in the family of DsRed homologs. Thus, sequencecomparisons between DsRed and its relatives can suggest mutations thatare likely to produce useful variants.

IV. Rapidly Maturing Variants of the Discosoma Red Fluorescent Protein(DsRed)

This section describes the multi-step mutagenesis strategy that was usedto obtain the optimized DsRed variants. An overview is provided inSupplementary Table 2.

One of the original N42H-containing mutants produced brighter colonyfluorescence than the other two. This increased brightness was due to asecond mutation: H41L. Residue 41 is a threonine in several homologuesof DsRed, and we found that an H41T substitution gives slightly brightercolonies than H41L. In the context of N42Q, H41T causes no significantchange in the properties of the purified protein (not shown) but appearsto yield a further increase in the maturation rate. Thus, after Round 1of the mutagenesis we had incorporated the two substitutions H41T andN42Q (Supplementary Table 1). The Round 1 variant generates a diffusehigh-molecular weight band when analyzed by nondenaturing SDS-PAGE(Supplementary FIG. 4A), suggesting that it is still tetrameric.

Additional rounds of mutagenesis were under-taken to accelerate thematuration further. Using the Round 1 variant as a template, we obtainedthree mutants that produced brighter E. coli colonies after one day ofgrowth. All three mutants contained the V44A substitution. In additionto accelerating chromophore formation, V44A reduces the blue excitationand green emission relative to the Round 1 variant (not shown). One ofthe three V44A mutants also contained a T21S substitution, which furtherdiminishes the blue excitation and green emission (not shown). Thus, theRound 2 variant contained the four substitutions T21S, H41T, N42Q andV44A (Supplementary Table 2). Round 3 of the muta-genesis producedseveral mutants with a further increase in colony fluorescence.Surprisingly, the relevant mutation did not alter the DsRed proteinitself, but instead was a proline-to-leucine codon change at position −4in the linker between the hexahistidine tag and the initiatormethionine. This result indicates that sequences appended to the Nterminus of DsRed can affect protein folding and/or chromophorematuration. The P(−4)L substitution was incorporated to yield the Round3 variant (Supplementary Table 2).

When purifying the fluorescent proteins, we noticed that DsRed and itsvariants were inefficiently extracted from E. coli cells under lysisconditions that extract most of the EGFP. This observation fits withreports that DsRed aggregates within cells. Round 4 of the mutagenesiswas designed to reduce this aggregation. We devised an assay in whichmutant bacterial clones were grown in 96-well plates, lysed with adetergent buffer, and spun to separate the extracted proteins from thebacterial pellets. The mutants of interest showed an increased ratio ofsoluble to insoluble red fluorescence. Of the more than 25 such mutantproteins identified, nearly all had a reduction in the net charge nearthe N terminus. After testing a number of mutant combinations, weincorporated the trio of substitutions R2A, K5E and N6D to yield theRound 4 variant (Supplementary Table 2).

To compare the solubilities of the different DsRed variants, weexpressed each protein in E. coli, lysed the cells in detergent buffer,and quantified the percentage of the protein molecules that wereextracted (Supplementary FIG. 4B). Virtually 100% of the EGFP moleculesare solubilized under these conditions. Only ˜25% of the DsRed1molecules are solubilized. DsRed2 is substantially more soluble (˜55%)than DsRed1. The Round 3 variant is also more soluble (˜52%) thanDsRed1, but the Round 4 variant shows even higher to solubility (˜73%).When analyzed by nondenaturing SDS-PAGE, the Round 3 variant generates adiffuse band that may reflect the formation of higher-order oligomerswhereas the Round 4 variant generates a sharp band at the positionpredicted for a tetramer (Supplementary FIG. 4A). These results suggestthat reducing the net charge near the N terminus of DsRed suppressesaggregation of the tetramers.

SUPPLEMENTARY TABLE 2 Relevant mutations in DsRed Mutations Final Roundof obtained mutations mutagenesis Goal of mutagenesis or examinedincorporated 1 Accelerating maturation N42H, N42Q N42Q H41L, H41T H41T 2Accelerating maturation, V44A V44A reducing green emission T21S T21S 3Accelerating maturation P(−4)L P(−4)L^(a) 4 Enhancing solubility R2H,R2L, R2A R2A^(b) K5E, K5Q, K5M K5E N6D N6D 5 Reducing green emissionT217A T217A^(c) 6 Reducing green emission C117S, C117A C117S^(d) A145P,A145S A145P^(d) ^(a)The proline codon at position −4 relative to thestart codon was contributed by the multiple cloning site in thepDsRed1-N1 vector. ^(b)The R2A substitution also eliminates the extravaline codon that is present after the start codon in DsRed1. ^(c)T217Ais present in DsRed.T1 and DsRed.T4, but not in DsRed.T3. ^(d)DsRed.T1contains C117S but not A145P, whereas DsRed.T3 and DsRed.T4 containA145P but not C117S.

The Round 4 variant still gives a noticeable bleed-through fluorescencewith GFP filter sets (not shown). Therefore, we undertook Round 5 of themutagenesis to reduce the green emission further. Flow cytometry wasused to select E. coli cells that showed bright fluorescence with anincreased ratio of red to green emission. All seven of the resultingmutants contained a T217A substitution. In addition to reducing the blueexcitation and green emission, T217A reverses the slight spectralred-shift observed with N42Q (see FIG. 4A in the main text). T217A wasincorporated to yield the Round 5 variant (Supplementary Table 2).

Finally, we took advantage of fortuitous observations from unrelatedmutagenesis experiments. The C117S substitution further reduces the blueexcitation and green emission. Thus, the optimized variant designatedDsRed.T1 contains the following substitutions: P(−4)L, R2A, K5E, N6D,T21S, H41T, N42Q, V44A, C117S and T217A. The A145P substitution issimilar to C117S in its effect on the fluorescence spectra, but in someDsRed mutant backgrounds, colony fluorescence is slightly decreased byC117S and slightly increased by A145P (not shown). Therefore, we createda second optimized variant called DsRed.T4, which is identical toDsRed.T1 except that the C117S substitution has been replaced withA145P. Subsequent analysis revealed that the advantages conferred byT217A are accom-panied by a modest decrease in brightness, so we createda third optimized mutant called DsRed.T3, which is identical to DsRed.T4except that DsRed.T3 lacks the T217A substitution.

The blue excitation and green emission are reduced by the T21S, V44A,C117S, A145P and T217A substitutions. Val44 and Thr217 face the interiorof the DsRed protein and are close to residue 42, indicating that theV44A and T217A substitutions relieve the steric constraints caused byN42Q. By contrast, Thr21, Cys117 and Ala145 face the surface of theDsRed monomer, so T21S, C117S and A145P are indicated as altering theoverall packing of the protein. T21S and A145P may influence DsRedstructure by modifying the tetramer interfaces.

It is evident from the above results and discussion that the presentinvention provides an important new class of fluorescent proteins thatrapidly mature. As such, the subject invention represents a significantcontribution to the art.

All publications and patent applications cited in this specification areherein incorporated by reference as if each individual publication orpatent application were specifically and individually indicated to beincorporated by reference. The citation of any publication is for itsdisclosure prior to the filing date and should not be construed as anadmission that the present invention is not entitled to antedate suchpublication by virtue of prior invention.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it is readily apparent to those of ordinary skill in theart in light of the teachings of this invention that certain changes andmodifications may be made thereto without departing from the spirit orscope of the appended claims.

What is claimed is:
 1. A nucleic acid that encodes a rapidly maturingchromo- or fluorescent mutant of a Cnidarian chromo- or fluorescentprotein or mutant thereof.
 2. The nucleic acid according to claim 1,wherein said Cnidarian chromo- or fluorescent protein is from anon-bioluminescent Cnidarian species.
 3. The nucleic acid according toclaim 2, wherein said non-bioluminescent Cnidarian species is anAnthozoan species.
 4. The nucleic acid according to claim 3, whereinsaid nucleic acid Anthozoan species is Discosoma.
 5. The nucleic acidaccording to claim 4, wherein said nucleic acid encodes a mutant ofDsRed.
 6. The nucleic acid according to claim 5, wherein said nucleicacid encodes a product having a point mutation at at least one ofposition 2, position 5, position 6, position 21, position 41, position42, position 44, and position 117 relative to wild type DsRed.
 7. Thenucleic acid according to claim 6, wherein said product is a producthaving a point mutation at at least one of position 145 and
 217. 8. Anucleic acid according to claim 7, wherein said nucleic acid has asequence of residues that is substantially the same as or identical to anucleotide sequence of at least 10 residues in length of SEQ ID NOS: 01or
 02. 9. A fragment of the nucleic acid selected according to claim 1.10. A construct comprising a vector and a nucleic acid according toclaim
 1. 11. An expression cassette comprising: (a) a transcriptionalinitiation region functional in an expression host; (b) a nucleic acidaccording to claim 1; and (c) and a transcriptional termination regionfunctional in said expression host.
 12. A cell, or the progeny thereof,comprising an expression cassette according to claim 11 as part of anextrachromosomal element or integrated into the genome of a host cell asa result of introduction of said expression cassette into said hostcell.
 13. A method of producing a chromo and/or fluorescent protein,said method comprising: growing a cell according to claim 12, wherebysaid protein is expressed; and isolating said protein substantially freeof other proteins.
 14. A protein or fragment thereof encoded by anucleic acid according to claim
 1. 15. An antibody binding specificallyto a protein according to claim
 14. 16. A transgenic cell or the progenythereof comprising a transgene that is a nucleic acid according toclaim
 1. 17. A transgenic organism comprising a transgene that is anucleic acid according to claim
 1. 18. In an application that employs achromo- or fluorescent protein, the improvement comprising: employing aprotein according to claim
 14. 19. In an application that employs anucleic acid encoding a chromo- or fluorescent protein, the improvementcomprising: employing a nucleic acid according to claim
 1. 20. A kitcomprising a nucleic acid according to claim 1.